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Medication errors are one of the most common causes of patient injuries in healthcare 
systems.  Poor labelling has been identified as a contributing factor of medication 
errors, particularly for those involving injectable drugs.  Colour coding and colour 
differentiation are two major techniques being used on labels to aid drug identification.  
However, neither approach has been scientifically proven to minimize the occurrence 
of or harm from medication errors.  This thesis investigates potential effects of 
different approaches for using colour on standardized labels on the task of identifying a 
specific drug from a storage area via a controlled experiment involving human users.  
Three different ways of using colour were compared: labels where only black, white 
and grey are used; labels where a unique colour scheme adopted from an existing 
manufacturer’s label is applied to each drug; colour coded labels based on the 
product’s strength level within the product line.  In addition to the drug identification 
task under normal conditions, the different approaches for using colour were compared 
in terms of the accuracy and the amount of time to complete the tasks under two 
conditions designed to induce human error.  These conditions simulated stocking 
errors involving the misplacement of a wrong drug with a look-alike, sound-alike name 
and also with a look-alike label as the correct drug at the place where the correct drug 
should have been, and the misplacement of two drugs of the same drug type but of 
different strengths in place of each other.  The results show that people might be 
vulnerable to confusion from drugs that have look-alike labels and also have look-alike, 
sound-alike drug names.  In particular, when each drug label had a fairly unique 
colour scheme, participants were more prone to misperceive the look-alike, sound-
alike drug name as the correct drug name than when no colour was used or when 
colour was used on the labels with no apparent one-to-one association between the 
label colour and the drug identity.  This result could suggest a perceptual bias to 
perceive stimuli as the expected stimuli especially when the task involved is familiar 
and the stimuli look similar to the expected stimuli.  Moreover, the results suggest a 
potential problem that may arise from standardizing existing labels if careful 
consideration is not given to the effects of reduced visual variations among the labels 
of different products on how the colours of the labels are perceived and used for drug 
identification.  The thesis concludes with recommendations for improving the 
existing standard for labelling of injectable drug containers and for avoiding 
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Medication errors frequently occur in healthcare systems and endanger patient safety 
(Aspden, Wolcott, Bootman, & Cronenwett, 2006; Phillips et al., 2001).  Injectable 
drugs have been involved in more than half of the medication errors reported by 
hospital pharmacists to the United States Pharmacopoeia from 1995 to1999 (United 
States Pharmacopoeia, 2000), and poor labelling has been identified as a major 
contributing factor in these errors (Cohen, 1999; Beverley A. Orser, Chen, & Yee, 
2001; United States Pharmacopoeia, 1998).   In Canada, a standard for labelling of 
drug ampoules, vials and prefilled syringes has been developed by the Canadian 
Standards Association (CSA) (Canadian Standards Association, 1999).  As the CSA 
standard requires the information critical for identifying and administrating injectable 
drugs to be printed in black characters on a white background, use of colour on 
medication labels is an important issue related to standardizing injectable drug labels 
following the standard.  Nevertheless, there is limited scientific literature to draw 
concrete conclusions on how colour should be used on medication labels to reduce the 
occurrence of medication errors.  This thesis examines the effects of three different 
ways of applying colour on injectable drug labels on people’s performance on 
identifying drugs using their labels. 
 
1.2 Focus of investigation 
The Canadian Standards Association (CSA) developed a standard for labelling of drug 
ampoules, vials and prefilled syringes in 1999 to address the problems with poor 
labelling of injectable drugs (CAN/CSA-Z264.2-99).  The CSA standard 
complements the requirements in the Food and Drug Act and Regulations by the 
Government of Canada (Government of Canada, 1985, 2006).  The Act and the 
Regulations focus on ensuring that pertinent information is presented on the labels 
while the CSA standard focuses on the design aspects related to how the information 
should be presented on the labels.  There is no legal requirement for manufacturers to 
comply with the requirements in the CSA standard.  Although there are some 
differences in the details of the requirements, the scope of the CSA standard is similar 
to the standards developed in the US by the American Society for Testing Materials 
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(for further discussion of the standards, see Section 2.2). 
 
 The CSA standard requires the information that is critical for the safe use of 
injectable drugs to be printed in black characters on a white background along with 
other typographical requirements (Clause 4.4.6, Canadian Standards Association, 
1999).  For parts of the label outside the critical information field, the CSA standard 
is not very specific about how colour should be used: 
The use of colours or trade dress is acceptable on labels, providing they do not 
intrude upon the critical information field or distract from the legibility of 
critical information. 
Note: While colour and graphics can be used to facilitate differentiation among 
the formulations of the same drug product, the best use of colour and graphics is 
to supplement legible label information. Black lettering on a white field is the 
most legible form of communication under daylight conditions (Clause 4.5.1, 
Canadian Standards Association, 1999). 
The labels of small-volume injectable drugs in ampoules or vials (LSVAV) are 
wrapped around on the rapidly curved surfaces of the containers.  Therefore, only the 
critical information field of a label may be visible before the container is picked up and 
rotated for careful reading.  If all the LSVAV followed the CSA standard, different 
products may look similar to each other with all of their labels showing the critical 
information field in black and white, unless there are other salient visual differences 
such as container shape.  This potentially increased similarity amongst different labels 
arising from standardization is closely related to the issue of using colour on 
medication labels. 
 
  Using colour on medication labels is highly controversial (Cohen, 2006; 
Institute for Safe Medication Practices, 2003b; Kenagy & Stein, 2001; US Food and 
Drug Administration, 2005).  In general, colour differentiation and colour coding are 
two major ways to apply colour on medication labels for individual drug identification.  
Colour differentiation is applying colour “to make certain features stand out, or to help 
distinguish one item from another” (Institute for Safe Medication Practices, 2003b).  
Colour differentiation is often recommended and used to differentiate products within 
the same product line.  For example, the label on a morphine product with a 
concentration of 40 mg/mL may have a green background colour while a morphine 
product with a concentration of 100 mg/mL has a red background colour.  Colour 
coding is “the systematic, standard application of a colour system to aid in the 
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classification and identification of drug products” (Institute for Safe Medication 
Practices, 2003b).  Colour coding by the therapeutic class of drugs is used and 
supported in a number of specialized areas in healthcare.  For example, for user-
applied labels on prefilled syringes in anaesthesia, blue is used as the background 
colour of the labels for narcotics, red for muscle relaxants, orange for hypnotics, etc 
(see Section 2.3.3 for more examples).  Colour differentiation is different from colour 
coding in that colour itself does not have any special meaning.  However, there is 
concern that colour can become a mental shortcut in the drug identification processes, 
encouraging people to identify drugs by the colour alone, rather than by reading the 
labels carefully (R. Filik, Purdy, & Gale, 2004; Institute for Safe Medication Practices, 
2003b; Jensen, Merry, Webster, Weller, & Larsson, 2004; Nunn & Baird, 1996).  As 
an alternative, black and white labels that are look-alike to each other have been 
suggested to remove the colour “shortcut” and to force users to always read and check 
the labels carefully as it would be the only way to identify drugs.  However, the 
disadvantage to the black and white labels may be that the potential advantages of 
using colour on labels may not occur.  It is difficult to predict which strategy could 
actually prevent drug identification errors. 
 
 Humans have a tendency to perceive information following their expectation 
even though the information may not correspond to their expectation.  This perceptual 
bias has been identified as a cause of human errors involving perceptual confusions in 
aviation (Shorrock, 2007) and in visual detection tasks in a simulated driving 
environment (Martens, 2004).  In particular, this perceptual bias has been identified as 
a possible contributing factor for medication errors involving drugs with look-alike 
labels and packaging or look-alike, sound-alike (LASA) drug names (Cohen, 1999, p. 
13.2; Davis, 1994; U, 2003).  The suggested mechanism of this bias is that, as users 
become familiar with the drugs they frequently handle, and each drug has a fairly 
unique colour scheme, users may develop expectations about drug identity based on 
the colour of the labels.  When the user unexpectedly encounters a wrong drug with a 
look-alike label and a LASA name, the user is likely to perceive the look-alike drug as 
the intended drug following his/her expectation.  Healthcare professionals, in 
particular, are expected to be vulnerable to this perceptual bias given their high level of 
familiarity with the drugs they use frequently and their stressful work environment 
according to Reason (1990). 
 
 This thesis aims to examine the potential effects of different ways of using 
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colour on a set of standardized labels via a controlled experiment involving human 
users.  Specifically, three different ways of using colour are compared: labels where 
only black, white and grey are used; labels where a unique colour scheme adopted 
from an existing manufacturer’s label is applied to each label; colour coded labels 
where the colour code indicates the strength level of the drug within the product line.  
The colour conditions are compared in terms of their effects on people’s performance 
on a visual search task that simulates the task of finding a specific drug from a storage 
area.   
 
 The contributions of this thesis can be summarized as follows: 
1. Examination of how different ways of using colour on medication labels can affect 
people’s performance on the drug identification task. 
2. Examination of the effects of different approaches to using colour on medication 
labels on people’s ability to differentiate drugs with look-alike labels and LASA 
names and their ability to identify misplaced drugs. 
3. Developing greater understanding of the human factors involved in the process of 
identifying drugs using their labels. 
4. Providing recommendations for improving the current Canadian standard for 
labelling of injectable drugs and medication safety in general. 
 
1.3 Structure of the thesis 
The remainder of this thesis is structured as follows: 
 
 Chapter 2 provides background information on how poor labelling contributes to 
medication errors, issues related to standardization of injectable drug labels and 
different ways of using colour on medication labels 
 Chapter 3 describes the scope and objectives of the thesis 
 Chapter 4 describes the materials, experimental design, participants, procedure 
and dependent measures used for the experiment 
 Chapter 5 shows the results of the experiment 
 Chapter 6 discusses the results and concludes with recommendations 




Chapter 2  
Background Review 
 
This chapter provides background information on medication errors and how labelling 
and packaging of drugs can contribute to these errors.  The Canadian and the US 
standards for designing labels for injectable drug containers in relation to using colour 
on the labels are discussed.  Different ways of applying colour on medication labels 
are described with a focus on colour coding and colour differentiation.  A perceptual 
bias involving expectation is hypothesized as a contributing factor of confusions 
involving drugs with look-alike labels and LASA drug names.  Further, possible 
effects of the bias on users when colour is used on the labels as well as when the labels 
are standardized are explored.     
 
2.1 Medication errors and poor labelling 
Medication errors are a serious issue in healthcare.  A medication error is defined as 
“any preventable event that may cause or lead to inappropriate medication use or 
patient harm while the medication is in the control of the healthcare professional, 
patient, or consumer” by the US National Coordinating Council for Medication Error 
Reporting and Prevention (2008).  According to a retrospective analysis of mortalities 
associated with the medication errors reported to the US Food and Drug 
Administration (FDA), 469 deaths were caused by the medication errors from 1993 to 
1998 (Phillips et al., 2001).  A recent report by the US Institute of Medicine estimates 
that about one medication error occurs per patient per day in hospital care (Aspden, 
Wolcott, Bootman, & Cronenwett, 2006, p. 111).  In Canada, Baker et al. (2004) 
conducted a national study of the incidence of adverse events across four acute care 
hospitals in each of the selected five provinces by reviewing the patient charts.  Drug- 
or fluid-related adverse events were the second most frequently related type of events 
to the identified adverse events following surgical procedures or events.  Furthermore, 
the study found that 36.9 % of the patients who experienced one or more adverse 
events had highly preventable adverse events.  The Institute for Safe Medication 
Practices Canada (ISMP Canada) has been collecting and analyzing voluntary 
medication error reports in Canada since 2000.  As of September 20, 2005, the ISMP 
Canada’s database had more than 10,000 medication error reports (Hyland, 2005).   
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 Poor labelling has been identified as a major contributing factor of medication 
errors, particularly those involving injectable drugs.  An analysis of 1,045 medication 
errors reported to the United States Pharmacopoeia (USP) Medication Errors Reporting 
(MER) Program from October, 1991 to September, 1994 revealed that 766 incidents 
involved injectable drugs, and 251 of the 766 incidents involved labelling issues 
(United States Pharmacopoeia, 1994).  Another analysis of the medication errors 
reported to the USP MER program from June 1, 1996 to May 31, 1997 showed that 
33 % of the reports (N = 560) cited labelling as a contributing factor (United States 
Pharmacopoeia, 1998).  Concerns over the labelling of injectable drugs led to the 
establishment of the joint USP/FDA Advisory Panel on Simplification and 
Improvement of Injection Labelling in 1991.  In Canada, Orser, Chen and Yee (2001) 
surveyed 687 Canadian anaesthesiologists about their experience with medication 
errors.  The misidentification of a syringe or “syringe swap” was reported as the most 
common cause of error (70.4 %) followed by a failure to read the label (62.9 %) and 
misidentification of the drug ampoule or vial (46.8 %).  In anaesthesia, potent 
injectable drugs are often pre-drawn from ampoules or vials into syringes before use 
and administered through complex procedures.  Therefore, wrong drug errors from 
the misidentification of a syringe or drug ampoules or vials have been the leading type 
of medication errors in anaesthesia (Abeysekera, Bergman, Kluger, & Short, 2005; 
Currie et al., 1993; B. A. Orser & Oxorn, 1994).   
 
2.2 Standardization of labels for injectable drugs   
To address this issue of poor labelling of injectable drugs, the Canadian Standards 
Association (CSA) developed a standard for labelling of injectable drug ampoules, 
vials and prefilled syringes in 1999 (Canadian Standards Association, 1999).  The 
CSA standard defines minimum design requirements for the presentation of critical 
information on the inner labels for injectable drug products in ampoules, vials or 
prefilled syringes, and complements but does not replace the requirements in the 
Canadian regulations (Government of Canada, 1985, 2006).  Complying with the 
requirements in the CSA standard is voluntary.   
 
 In the US, the American Society for Testing Materials (ASTM) International 
has developed several standards relevant to the labelling of injectable drug containers.  
ASTM D4267-07 specifies the orientation, type size and the contrast of label contents 
for the labels of small-volume (100 mL or less) injectable drug containers.  The 
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standard discourages using pastel shades such as pink, green, brown or grey for copy, 
and other colours of these shades for background (Clause 7.1, American Society for 
Testing and Materials, 2007b).  ASTM D6398-01e1 specifies the shape, size, colour, 
layout, typeface and bar coding on the labels for prescription drug packaging.  
Consistent with ASTM D4267-07, ASTM D6398-01e1 states that “pastel colours 
should not be used for the identification of drugs…” (Clause 6.2, American Society for 
Testing and Materials, 2001).  Furthermore, the standard recommends “colour 
contrasts with bright saturated colours contrasting with the text and the background” 
with the following suggested text-background colour pairs: black-white, blue-yellow, 
white-blue and blue-white (Clause 6.3, American Society for Testing and Materials, 
2001).  ASTM D4775-04 specifies the labelling requirements for identification and 
configuration of prefilled syringes (American Society for Testing and Materials, 2004).  
ASTM D5022-07 defines the requirements for identification of vials and ampoules 
containing drugs to be diluted before use (American Society for Testing and Materials, 
2007a).  Both ASTM 4775-04 and D5022-07 requires the words “Dilute Before Use”, 
or similar warning, to be printed within a red box whenever space permits for the 
containers with concentrated drugs to be diluted before use (Clause 6.2, American 
Society for Testing and Materials, 2004; Clause 4.2, American Society for Testing and 
Materials, 2007a). 
 
 For information that is considered critical for the identification and safe 
administration of injectable drugs, the requirements concerning using colour on the 
labels in the CSA standard is more stringent compared to the requirements in the 
ASTM standards.  The CSA standard defines the critical information as the drug’s 
common name(s) in English and French and the total amount of drug ingredient(s) as 
mg per total millilitres, followed by the concentration of drug ingredient(s) as mg per 
one mL.  The standard requires the critical information to be printed in black 
characters on a white background.  The black and white colour scheme provides a 
high contrast between characters and a background, and therefore ensures a high level 
of legibility of the critical information.  However, if all the labels for injectable drugs 
in small-volume ampoules and vials (LSVAV) followed the standard, labels of different 
drugs may look very similar to each other since the critical information field which 
makes up a large portion of the labels would all bear the same type colour and the 
background colour.  The LSVAV are wrapped around on rapidly curved surfaces, and 
thus only the critical information field may be visible when arranged on a shelf as 
illustrated in Figure 1.  Therefore, if all the LSVAV followed the standard, the 
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legibility of an individual label may be ensured, but finding a specific drug from a 
storage area may become difficult. 
 
 
Figure 1: A picture of 1 mL ampoules with a set of standardized black and white labels 
following the CSA standard 
 
 In fact, the issue of whether this type of increased similarity amongst 
medication labels from eliminating colour decreases or increases the risk of medication 
errors remains unresolved.  One view is that no colour should be used on medication 
labels and that injectable drug containers should come in the same sizes and in the 
same shape.  This way, reading the label carefully would be the only way to identify a 
drug, and the number of errors related to confusing one drug product from another may 
be reduced.  It is argued that using colour can undermine the process of reading and 
checking the labels carefully (Aono & Ueda, 2000; Nunn & Baird, 1996).  M. R. 
Cohen of the Institute for Safe Medication Practices (ISMP) suggests this possibility 
by providing an example that no errors have been linked to unit dose packages 
produced by automated packaging and dispensing machines despite the fact that the 
unit dose packages are identically labelled, of the same size and shape for all products 
(Cohen, 2006, p. 123).  A contrary view is that the process of humans reading and 
checking the labels are bound to fail sometimes, and there needs to be a systematic 
measure such as colour coding to minimize the occurrence of or harm from human 
errors involved in the label reading process (Abeysekera, Bergman, Kluger, & Short, 
2005; B. A. Orser & Oxorn, 1994; Webster, 2000).  
 
 In general, there are three ways of using colour on medication labels and 
packages; colour differentiation, colour coding and colour matching.  Colour 
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differentiation is applying colour to emphasize certain features of the label/package or 
to distinguish one drug product from another (Institute for Safe Medication Practices, 
2003b).  For example, a product warning that a concentrated drug must be diluted 
may be highlighted on the label by printing a warning message such as “Dilute before 
use” in red characters.  Colour differentiation is different from colour coding in that 
colour itself does not have any special meaning.  For example, Figure 2 shows the 
labels of two different strengths of hydromophone hydrochloride injection products 
differentiated by their background colours; the label for 10 mg/mL has a green 
background colour while the label for 20 mg/mL has an orange background colour.  
The green and orange themselves, however, do not mean anything.  Colour coding is 
“the systematic, standard application of a colour system to aid in the classification and 
identification of drug products” (Institute for Safe Medication Practices, 2003b).  
Therefore, “a colour coding system allows people to memorize a colour and match it to 
its function” (Institute for Safe Medication Practices, 2003b).  For example, the USP 
and the FDA require the vials containing potassium chloride for injection concentrate 
to have a black metal closure with a black cap and the ampoules to have a black 
band(s) above the constriction (Cohen, 2006, p. 147; Council on Science and Public 
Health, 2004).  The requirement is also a part of the ASTM standard D5022-07 
(American Society for Testing and Materials, 2007a).  No other drug is to be 
packaged with a black band(s) in an ampoule or with a black cap in a vial.  Colour 
matching is applying the same or similar colours to more than one drug products that 
are related to each other.  It has potential for reducing medication errors although not 
directly related to the identification of individual products.  For example, Berwith, 
Sinz, Chase and Martin (2007) examined the speed and accuracy of drawing drugs 
from vials to corresponding syringes with three different labels that were black and 
white, colour matched and colour mismatched in a controlled simulated study.  The 
number of near misses with colour matched labels was significantly fewer than that 
with the black and white labels or with the colour mismatched labels.  Since colour 
differentiation and colour coding are most relevant to the LSVAV and medication 




Figure 2: Pictures of hydromorphone hydrochloride injection vials with the concentration 
of 10 mg/mL (left) and of 20 mg/mL (right)  
 
2.3 Colour coding 
Colour coding is an integral component of safety warnings, labels and tags.  For 
warnings in general, there are colour coding systems for informing users of the type or 
hazard level of the warnings.  For medication labels, colour coding is used in 
specialized areas of medicine to indicate the therapeutic class of drugs.  Due to 
limited scientific evidence, authorities in medication safety either do not support colour 
coding or advise caution when applying colour coding on medication labels. 
 
2.3.1 Colour coding in warnings in general 
The International Organization for Standardization (ISO)’s safety sign system use 
colour-coded surround shapes to inform the viewers the meaning of the type of sign 
(Peckham, 2006a).  A yellow triangle is used for a warning sign, a blue circle is used 
for a mandatory action sign, and a red outline circle with a diagonal slash is used for a 
prohibition sign.  In the US, the American National Standards Institute (ANSI)’s Z535 
standards provide guidelines for developing warning signs, labels and tags (Peckham, 
2006b).  ANSI Z535.1 Safety Colour Code defines the colour tolerance boundaries 
for safety colours.  The colours are used by other ANSI Z535 standards as the 
background of the signal word panels to communicate the hazard seriousness level; red 
for DANGER, orange for WARNING and yellow for CAUTION (see Figure 3 for 
examples).  In Canada, CAN/CSA-Z321-96 standard defines the requirements for the 
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design of signs that are to be used in the workplace for the purpose of communicating a 
regulatory, warning or information message (Canadian Standards Association, 1996).  
The standard specifies a set of colours for six sign categories as follows: 
1. Prohibition: red and black on white; 
2. Mandatory: white on black; 
3. Caution: black on yellow; 
4. Danger: white on red; 
5. Emergency: white on green; and 
6. General information: white on blue. 
 
 
Figure 3: ANSI Z535 safety sign and label formats  
(Peckham, 2002) 
 
2.3.2 Research activities on colour coding of warnings 
The research in warnings largely supports using colour to convey hazard level on 
warnings.  Kline, Braun, Peterson and Silver (1993) found that coloured labels were 
perceived as more readable and hazardous than black and white labels.  Smith-
Jackson and Wogalter (2000) presented ten colours from the ANSI Z535.1 safety color 
standard to participants, and participants were asked to rate how careful they would be 
if they saw the colour on a sign, poster or label.  They found a significant effect of 
colour on the carefulness ratings; red, yellow, black, orange and magenta were given 
the five highest hazard ratings (in the order of decreasing hazard level) that were 
significantly different from each other except for yellow and black.  Braun and Silver 
(1995) also applied five safety colours (red, orange, blue, green and black) from the 
ANSI Z535.1 standard to five safety words and asked 30 participants to rate their 
perceived hazard level.  Red was perceived to be the most hazardous compared to all 
the other colours, and orange was perceived to be significantly more hazardous than 
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black, green or blue.  Adams and Edworthy (1995) also found that the signal word 
WARNING printed in black would have to be approximately twice as big as that in red 
to give the same perceived urgency.   
 
2.3.3 Colour coding in medication labels 
For medication labelling, there are two major colour coding systems developed to 
reduce medication errors; a colour coding system for ophthalmic medications and a 
colour coding system for user-applied labels on syringes in anaesthesia.  The 
American Academy of Ophthalmology introduced a policy that endorses the uniform 
use of a colour coding system for the caps and the labels of topical ocular medications 
in 1996 (American Academy of Ophthalmology, 2006).  The purpose of the colour 
coding system is to help patients distinguish between various medications, and thus 
prevent serious medication errors.  The colour coding system was developed with the 
support of the pharmaceutical industry and the FDA.  In the colour coding system, 
different Pantone® colours are assigned to different classes of ocular medications as 
shown in Table 1.  With the endorsement by the American Academy of 
Ophthalmology, manufacturers in the US have been voluntarily converting to the 
colour coding system.   
  
 Despite of its intended purpose, the colour coding system may contribute to 
medication errors due to confusions amongst drugs within the same class.  The ISMP 
reportedly received many reports of mix-ups between different products of the same 
class (Institute for Safe Medication Practices, 1998, 2003a, 2003b).  It has been 
argued that while the colour coding system may be effective in the environment of a 
clinician’s office or a patient’s home, it is not appropriate to be used in pharmacies or 
in nursing units where a large number of products within the same class are handled 
(Institute for Safe Medication Practices, 2003a). 
 
 In addition to ophthalmology, colour coding has gained much attention in 
anaesthesia due to a large number of medication errors that involve identifying 
syringes, ampoules and vials.  To reduce the number of syringe swaps, an 
international colour coding system for user-applied labels on prefilled syringes in 
anaesthesia has been established.  In the colour coding system, different drug classes 
are assigned different Pantone® colours as shown in Figure 4.  The system is used in 
and recommend by the authorities around the world including the US, Australia, New 
Zealand, Canada and the UK (American Society for Testing and Materials, 2006; 
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Canadian Standards Association, 1998; Royal College of Anaesthetists, 2003; 
Standards New Zealand, 1998). 
 
Class Colour Pantone® Number 
Anti-infectives Tan 467 
Anti-inflammatories/steroids Pink 197 
Mydriatics and cycloplegics Red 1797 
Nonsteroidal anti-inflammatories Gray 4 
Miotics Dark Green 348 
Beta-blockers Yellow Yellow C 
Beta-blocker combinations Dark Blue 281 
Adrenergic agonists Purple 2583 
Carbonic anhydrase inhibitors Orange 1585 
Prostaglandin analogues Turquoise 326 
Table 1: The colour coding system for topical ophthalmic medications 
 
 
Figure 4: The international colour coding system for user-applied labels on syringes in 
anaesthesia adopted in the UK  
(Royal College of Anaesthetists, 2003) 
 
 Nonetheless, the effectiveness of the syringe labelling colour coding system 
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in reducing the number of medication errors has been controversial.  Jensen, Merry, 
Webster, Weller and Larsson (2004) performed a systematic literature review to come 
up with evidence-based recommendations for the minimization of intravenous drug 
administration errors in anaesthesia.  The recommendations were validated using the 
reports of medication errors from two tertiary teaching hospitals in New Zealand.   
One of their recommendations was "colour coding by class of drug according to an 
agreed national or international standard should be used – of the syringe, part of the 
syringe, or of the syringe or ampoule labels” (Jensen et al., 2004).  The 
recommendation, however, was weakly supported in their study due to the conflicting 
views in the literature on the issue of colour coding.  Twenty-one authorities 
supported the recommendation in principle while seven authorities did not support it.  
The authorities who opposed the use of colour coding were concerned that colour 
coding may detract users from reading the labels carefully, which they believed to be 
the sole or at least the central strategy for correctly administrating an intravenous drug.  
However, the vast majority of the studies supporting or opposing the use of colour 
coding reviewed in the study did not involve an experimental design or an analysis of 
prospectively collected medication error reports.  Rather, the studies were mostly case 
reports and/or expert opinions. 
 
 Due to the limited scientific evidence in the effectiveness of colour coding 
systems in reducing medication errors, many authorities involved in medication safety 
either discourage using colour coding systems or recommend caution in applying them 
(American Society of Health-System Pharmacists; Cohen, 1999, p. 13.6-13.8; Institute 
for Safe Medication Practices, 2003b; National Patient Safety Agency, 2007, p. 55; US 
Food and Drug Administration, 2005).  For example, the FDA held a public hearing 
on the use of colour on pharmaceutical product labels, labelling and packaging on 
March 7, 2005, where the representatives from pharmaceutical manufacturers, 
physicians from different disciplines and organizations involved in medication safety 
discussed the issue.  The USP, the ISMP, the American Society of Health-System 
Pharmacists and two manufacturers expressed concern over using colour coding while 
the American Dental Association and American Academy of Ophthalmology supported 
their colour coding systems (US Food and Drug Administration, 2005) 
 
2.3.4 Summary 
Colour coding systems that assign colour to product labels based on drug classes may 
help reduce medication errors from mixing up drugs from different classes in certain 
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contexts.  However, such systems may increase the number of medication errors due 
to intra-class mix-ups.  In addition, the use of colour coding is limited in many ways.  
There are only a limited number of highly distinguishable colours by human eyes in 
comparison to the ever increasing number of marketed medications.  The same colour 
can look different under different lighting conditions.  Also, it is difficult to reproduce 
Pantone® colours exactly every time.  Finally, people may not read the labels 
carefully after using the colour coding system to quickly differentiate products of 
different classes. 
 
2.4 Colour Differentiation 
The effectiveness of colour differentiation in reducing medication errors has not been 
scientifically proven either.  Nevertheless, colour differentiation is widely used by 
manufacturers of injectable drugs to distinguish drug products of different strengths or 
of type within the same product line or to emphasize certain features of the labels.   
 
2.4.1 Current Practices 
As part of a related prior study, seventy-eight injectable drugs were collected from a 
pharmacy inventory of a large urban hospital (Momtahan, Burns, Hyland, Jeon, & 
Gabriele, 2008).  While these samples were collected for the other study, it was also 
possible to examine them to look at current practices of colour differentiation.  An 
analysis of the sampled labels revealed that 75 % of them emphasized either the drug 
strength (for drugs in solution or liquid) or the total mass (for drugs in powder) on the 
label (N = 77, one sterile water sample was irrelevant for this analysis) by using colour 
differentiation.  A different type colour and a background colour from those used in 
the vicinity of the field displaying drug strength or total mass were used to highlight 
the information.  Figure 5 shows such samples.  Also as a part of the study, nine 
injectable drug products that use different type colour and/or background colour for 
expressing different strengths or amounts within the product line were found.  Figure 
6 shows three of the nine samples.   
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Figure 6: Samples using colour differentiation to differentiate multiple products within 
the same product line 
  
2.4.2 Supports for colour differentiation 
In comparison to colour coding, colour differentiation is more strongly supported by 
pharmaceutical manufacturers and authorities related to medication safety.  At the 
FDA’s public hearing on the use of colour on pharmaceutical product labels, labelling 
and packaging, the representatives from two major pharmaceutical manufacturers 
expressed their support for using colour differentiation on medication labels (US Food 
and Drug Administration, 2005).  While cautioning any method of using colour on 
medication labels should be carefully thought through, M. R. Cohen of the ISMP also 
illustrated that colour differentiation can be helpful for distinguishing different products 
within the same product line and to draw attention to an important portion of the label 
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using examples as shown in Figure 7 at the FDA’s public hearing (US Food and Drug 
Administration, 2005).  The UK National Patient Safety Agency also supports using 
colour differentiation to distinguish medications within a product range (National 
Patient Safety Agency, 2007).  Similarly, the Therapeutic Goods Administration of 
Australia encourages using different colours or colour bars to distinguish between 
different strengths or presentations of the product range in its best practice guideline for 
prescription medication labelling (Therapeutic Goods Administration, 2005).  
Furthermore, the CSA standard allows the use of colour differentiation as it states 
“While colour and graphics can be used to facilitate differentiation among the 
formulations of the same drug product, the best use of colour and graphics is to 




Figure 7: A picture of Adrenalin® chloride solution for topical application and for 
hypodermic use prior to (left) and after (right) applying colour differentiation  
© 2005 ISMP 
 
2.4.3 An empirical study of colour differentiation 
To the best of the author’s knowledge, there has been only one controlled experiment 
that looks into the effects of colour differentiation on medication labels.  Filik, Purdy, 
Gale and Gerrett (2004) conducted two preliminary experiments investigating pros and 
cons of using colour to differentiate drugs of different strengths within the same 
product line.  In Experiment 1, participants were shown the image of a target drug 
pack on a computer screen for a limited amount of time and were shown eight different 
strengths of the target drug arranged in a circular manner.  During 50 % of the trials, a 
pack of the target strength was present in the array while during the remaining 50 % of 
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the trials, it was not.  Also, during half of the trials, all the packs had a grey block 
above the strength statement (the grey condition) while during the other half of the 
trials, the packs of different strengths had the blocks in different colours (the colour 
condition).  Figure 8 shows a sample drug pack used in the grey condition.  
Participants were given as much time as needed to input their response using the key 
buttons.  The accuracy of the responses was higher in the colour condition than in the 
grey condition by approximately 5 %.  In Experiment 2, the target pack was never 
present in the array but a product with a similar name, the same strength and the same 
colour as the target was presented.  The procedure was identical to that of Experiment 
1.  Participants made more errors in the colour condition than in the grey condition 
approximately with a 10 % difference in accuracy.  The statistical significance level 
of the accuracy differences in the two experiments were not reported in the paper.  
Based on these results, Filik et al. (2004) concluded that while colour can facilitate 
identifying a product of a particular strength within a range, colour could be used as a 
mental shortcut in the process of identifying a medication rather than reading the label 
carefully.   
 
 
Figure 8: An example drug pack used by Filik et al. (2004) 
 
 Filik et al. (2004)’s effort is laudable in that they explore pros and cons of 
using colour differentiation on medication labels via a controlled experiment.   
However, their study is limited in a number of ways to apply their results directly to 
the LSVAV.  First of all, the task was remote from the real-world tasks as 
acknowledged by the authors.  Participants were shown an image of the target drug 
pack just before the search task rather than given information about the target.  
Furthermore, the block was positioned at the bottom-right corner of each label while 
the drug name was positioned at the top-left side of the label.  Therefore, it is possible 
that the particular method of applying colour on the labels with a large distance 
between the drug name the coloured element contributed to the large difference in 
accuracy between the grey condition and the colour condition in Experiment 2.  
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Moreover, the drug packs were arranged in a circular manner while drugs are usually 
stored on flat surfaces in a row.  The drug packs used by Filik et al. (2004) displayed 
only the drug name, the drug form (tablets), strength in milligrams and the number of 
tablets.  Compared to the amount of space available on the packs, the amount of 
information displayed was small, and therefore the packs had a large amount of white 
surface.  In contrast, the LSVAV display a lot of information within a very limited 
surface area.  It is also rare to find an injectable medication that has as many as eight 
different strengths as those used in Filik et al. (2004)’s study.  A review of the drug 
formulary from a large urban hospital revealed that most injectable medications in 
ampoules or vials have three or less number of different strengths.   
  
2.4.4 Summary 
Using colour differentiation to help distinguish medications within the same product 
line is supported by manufacturers and some authorities of medication safety while the 
scientific evidence illustrating its effectiveness is very limited.  Nonetheless, given 
the limited number of highly distinguishable colours and the ever increasing number of 
marketed pharmaceutical products, there are bound to be products that share similar or 
the same colour(s) and may be confused. 
 
2.5 Perception errors 
Medication errors involved in confusing a wrong drug with a look-alike label/package 
is closely related to perception errors involved in both ‘bottom-up’ and ‘top-down’ 
processes of human information processing.  Humans have tendency to perceive 
information as their expectation even though the information may not correspond to 
their expectation.  This perceptual bias is called in a number of different ways.   
 
2.5.1 Expectation bias in air traffic control and driving 
Shorrock and Kirwan (2002) developed a human error identification technique for the 
retrospective and predictive analysis of cognitive errors in air traffic control called 
TRACEr.  Within TRACEr, people’s tendency to perceive what they expect to 
perceive is termed ‘expectation bias’.  Shorrock and Kirwan (2002) analyzed 
interviews with UK air traffic controllers and UK aircraft proximity incident reports 
using TRACEr, and found that controllers sometimes failed to notice inaccuracies in a 
pilot’s readbacks since most readbacks are correct.  Similar effect of expectation has 
also been observed in visual search tasks by Martens (2004) in a simulated driving 
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environment.  When targets appeared when participants expected them to be 
distractors, participants took longer to respond to the unexpected targets than the 
expected targets or did not respond to the unexpected targets at all. 
  
2.5.2 Expectation bias in medication errors 
The perceptual bias from expectation is most likely lead to errors when the stimuli look 
similar to the expected stimuli and when the task is familiar to the individual.  James 
Reason, a leading expert on human error, identifies mental slips that occur when a 
familiar task is performed in a largely automatic manner where “the recognition 
schemata accept as a match for the proper object something that looks like it, is in the 
expected location or does a similar job” (Reason, 1990, p. 72).  He termed this type of 
human error ‘perceptual confusion’.  In the medication error literature, the perceptual 
bias is called ‘confirmation bias’ (Cohen, 1999, p. 13.2-13.3; Davis, 1994; U, 2003).  
Confusing drugs with look-alike labels/packaging and/or LASA name is attributed to 
this phenomenon.  For example, three infants died from heparin overdoses at a 
hospital in the US in 2006 (Institute for Safe Medication Practices, 2006b).  The 
incident occurred due to a combination of factors but largely because a pharmacy 
technician had misplaced 1 mL vials of heparin containing 10,000 units/mL to where 1 
mL vials of heparin of 10 units/mL were normally kept.  Although several nurses 
were involved in the incident, none of them noticed that the vials were of the wrong 
concentration.  Figure 9 shows the pictures of the heparin containers involved in the 
incident.  The two containers are of the same size, have similar cap colours and use 
similar shades of the same colour.  Similar errors involving mixing up heparin 
products of wrong concentrations that have similar labelling/packaging continue to 
occur (Institute for Safe Medication Practices, 2007). 
 
 
Figure 9: Picture of heparin vials involved in the overdose error  
(Institute for Safe Medication Practices, 2006b) 
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 The use of term ‘confirmation bias’ can be misleading since the term is used 
somewhat differently outside the medication error literature.  Confirmation bias is 
more commonly used to describe people’s “unwitting selectivity in the acquisition and 
use of evidence” in a more conscious and effortful problem solving processes 
(Nickerson, 1998; Reason, 1990, p. 86).  For example, confirmation bias is used to 
describe “the tendency to focus on evidence that supports a working hypothesis, such 
as a diagnosis in clinical medicine, rather than to look for evidence that refutes it or 
provides greater support to an alternative diagnosis” by the US Agency for Healthcare 
Research and Quality (AHRQ) (Agency for Healthcare Research and Quality, 2008).  
Therefore, for the purposes of this thesis, the perceptual bias to interpret stimuli as 
expected especially with familiar tasks and look-alike stimuli will be called 
‘expectancy-based perceptual confusion’. 
 
2.5.3 Expectation bias and colour 
Expectancy-based perceptual confusion is likely to influence the cognitive processes 
involved in identifying drugs when their labels use colour.  The logic behind colour 
differentiation is letting people use colour to quickly differentiate one drug from 
another, and then read the label carefully to verify that it is the correct drug.  The 
problem is that while most pharmaceutical products look different (at least within a 
fixed range of products that a healthcare professional frequently uses) there are a few 
products that look similar to each other.  As healthcare professionals become familiar 
with the drugs they use, the look of the drug containers and where the drugs are stored, 
they would develop strong expectation about the drug identity when they select a 
product based on the look of its label and its location.  Therefore, when a healthcare 
professional is encountered with a drug with look-alike label/packaging at the location 
of the intended drug, he/she is likely to misread the label content as the drug that is 
looked for when the label is read for verification.  If all the labels look identical with 
no colours applied, the user would not likely develop an expectation as strong as when 
different products are approximately identifiable by their look alone.  Thus, when a 
wrong drug with a look-alike label is misplaced at the intended drug’s location, the 
individual may be less likely to misread the information as the target drug than when 
no colour is used on the products. 
  
 In fact, labelling/packaging colour seems to be an important factor that 
created confusions in medication errors involving drugs with look-alike 
labelling/packaging.  The cases involving similar labelling/packaging reported to the 
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USP MER program from July to December 2003 are shown in Figure 10 (Santell & 
Camp, 2004; United States Pharmacopoeia, 2004).  The similarity in colour is the 
predominant feature in all the labels shown in Figure 10 as well as the other cases 
reported to the USP MER that are not shown here (for the photos of the other cases see 
Santell & Camp (2004) and United States Pharmacopoeia (2004)).  Some of the labels 
in Figure 10 may not look too similar to each other to cause errors.  However, 
healthcare professionals usually deal with a limited variety of drugs that are stored at 
fixed locations depending on the unit they belong to, the type of healthcare facility and 
their speciality.  Healthcare professionals’ high-level of familiarity with a fixed set of 
drugs means that the drug identification would be largely automated with degraded 
stimuli acceptance criteria following their expectation.  Consequently, two reasonably 




Figure 10: Samples of drugs with look-alike labelling/packaging reported to the USP 
(the top two photos from United States Pharmacopoeia (2004) and the bottom two photos 
from Santell & Camp (2004)) 
 
2.6 Problems with look-alike, sound-alike drug names 
In addition to look-alike labelling/packaging, healthcare professionals are exposed to 
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perception errors from LASA drug names.  Wrong drug errors frequently occur due to 
confusions of LASA drug names.  The World Health Organization (WHO) 
Collaborating Centre for Patient Safety Solutions identified that LASA drug names as a 
significant cause of medication errors worldwide, and proposed actions for addressing 
the issue in their Nine Patient Safety Solutions, which was launched in May 2007 
(World Health Organization, 2007).   In 2001, the FDA’s Center for Drug Evaluation 
and Research conducted the Name Differentiation Project.  As an outcome of the 
project, the Office of Generic Drugs requested manufacturers of 16 look-alike name 
pairs to voluntary change the appearance of the drug names (US Food and Drug 
Administration, 2002).  Furthermore, the US Joint Commission on Accreditation of 
Healthcare Organizations (JCAHO) has required the accredited hospitals to “identify 
and, at a minimum, annually review a list of LASA drugs used in the organization, and 
take action to prevent errors involving the interchange of these drugs” since 2005 and 
maintains a list of LASA drug names (Joint Commission on Accreditation of 
Healthcare Organizations, 2008a; , 2008b, Requirement 3C).  The ISMP also keeps a 
list of confused drug names (Institute for Safe Medication Practices, 2006a).    
 
2.7 Standardization and using colour on medication labels 
If all the LSVAV followed the CSA standard, the colour of a label outside the critical 
information field can become an important factor that distinguishes one product from 
another.  The space outside the critical information field would be limited, and so 
would be the use of trade dress.  The variation in type size and layout is inherently 
limited for the LSVAV due to the limited surface area on the containers.  Moreover, 
there is not much variation in shape and size for ampoules and vials of a specific 
volume, especially within products from the same manufacturer.  Consequently, the 
colour of the non-critical information field would likely become a salient feature 
distinguishing different products when a product is selected based on its look first 
before being reading carefully for verification. 
 
 If care is not given to visual features other than colour that differentiate one 
product label from another (e.g. type font, use of graphics, layout, etc.) when 
standardizing the labels following the CSA standard, currently colour differentiated 
products from a single manufacturer may produce the effects of colour coding.  This 
is especially likely if it is ensured that products that are placed in the vicinity of each 
other do not use similar colour schemes.  Then, at least within a limited range of 
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products, users would likely associate each colour scheme with a unique drug identity. 
  
 Regardless of whether colour is used or not with standardization, the legibility 
of individual labels would be high.  Therefore, it is possible that users will correctly 
identify products whether their labels look similar to each other or not.  On the other 
hand, if colour is used on the standardized labels in a manner that allows users to 
create one-to-one association between the colour scheme of a label and a unique drug, 
it is difficult to believe that users will not be affected by the perceptual bias to perceive 
information following their expectation. 
 
2.8 Summary and motivation 
Although there exists a standard for labelling of injectable drug containers in Canada, 
its effectiveness in reducing the number of medication errors if all the LSVAV followed 
the standard is unclear.  If all the LSVAV were standardized following the CSA 
standard, different drugs may look very similar to each other due to the requirement to 
have the critical information field in black characters on a white background.  Also, 
due to reduced possible variation amongst different labels, colour may become a 
stronger feature differentiating the labels than it is for the current LSVAV.  The 
potential fallout from standardizing the LSVAV begs the question of how different 
ways of using colour on medication labels can affect users when identifying drugs 
using their labels. 
  
 Unfortunately, there is limited and mixed scientific evidence of how colour 
should be used on medication labels to minimize the occurrence of medication errors.  
Specifically, the use of colour coding and colour differentiation on medication labels is 
a much debated issue in healthcare.  Colour coding is used and supported in a number 
of specialized areas in healthcare, but there is concern that colour coding based on drug 
class may increase intra-class mix-ups.  Colour differentiation is more largely 
supported by healthcare professionals, pharmaceutical manufacturers and a number of 
authorities in healthcare.  Nevertheless, colour differentiation is exposed to the 
inherent limitations with using colour on medication labels including a limited number 
of highly discernable colours by human eyes, different perception of colour by person 
to person and depending on lighting condition, limited precision in colour reproduction 
and possibility of users not reading the labels carefully by relying on colour. 
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 A major concern with any method of using colour on medication labels is that 
colour can become a mental shortcut in the drug identification processes rather than 
reading the label carefully and/or lead people to misperceive similar labels by 
triggering expectancy-based perceptual confusion.  Monochrome labels that do not 
use any colour have been suggested to eliminate these possibilities.  It seems possible, 
however, that a colour coding system that codes different strength levels within the 
same product line but applied across all products may ensure that users read the labels 
carefully and minimize potential for expectancy-based perceptual confusion.  Most 
injectable drugs do not have more than three levels of strength, and therefore, such 
colour coding system would only consist of four colours (e.g. grey for single-level 
drugs, blue for the lowest strength level , yellow for the next strength level and red for 
the highest strength level within the product line).  If all the LSVAV were colour 
coded using this type of ‘strength colour coding system’, it would be obvious to users 
that it is impossible to rely on colour alone to identify a drug as there would be many 
drugs that share the same colours in the vicinity of each other.  Therefore, users 
would have to read the labels carefully to identify drugs.  Also, they may not be 
affected by expectancy-based perceptual confusion significantly since they cannot 
formulate a strong expectation about the drug identity based on colour alone. 
 
 To investigate the effects of different ways of applying colour on medication 
labels rather than based on speculations, a controlled experiment involving human 
users is a fundamental step; yet, the method has been largely underutilized in 
healthcare.  This research aims to examine the potential effects of three different ways 
of using colour on a set of standardized LSVAV in a controlled experiment setting.  
Standardized labels using no colour (i.e. black, white and grey only), those using 
colour schemes from the existing LSVAV and those using a strength colour coding 
system are compared in terms of their effects on people’s performance on a visual 




Scope and Objectives 
 
This thesis investigates the effects of three different ways of using colour on 
performing the task of searching for an injectable drug from a storage area under the 
scenario that all the labels are standardized.  The three different ways of using colour 
include monochrome, existing and colour coding of strength (SCC).   
1. Monochrome: all the characters are printed in black on a white background or on a 
light grey background.   
2. Existing: different background colour schemes used by some of the existing 
LSVAV from a major manufacturer of injectable drugs are applied as the 
background colours for different drug labels.   
3. Strength colour coding: a colour coding system where different colours are 
assigned to different strength levels within the same drug type is applied to all the 
labels.  The coding of drug strength is explored since there are only a limited 
number of different strength levels for most injectable drug products, and 
therefore only a few highly distinguishable colours are required.  Also, the 
coding of drug strength makes it apparent that there is no one-to-one relationship 
between the colours of the labels and the drug identity. 
 
 Participants were randomly assigned to one of the three colour conditions.  
The visual search task involved reading a target drug name and strength information, 
and finding a label that corresponds to the target drug information from a set of six 
labels displayed on a monitor.  The task was conducted under three different 
scenarios: target trials, name-foil trials and location-foil trials.   
1. Target trials: a label that matches the target drug information existed in the set of 
labels displayed.   
2. Name-foil trials: the target label was replaced with a label for a different drug with 
a LASA name while everything else about the label was identical to the target 
drug label.   
3. Location-foil trials: the location of the target drug label was swapped with the 
location of a label for the same drug but of a different strength.  
The two types of foil trials were designed to investigate the resilience of each way of 
using colour to two of the most common conditions prone to medication errors: when a 
wrong drug of a LASA name and a look-alike label is misplaced and when the drugs of 
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different strengths with the same product line are misplaced. 
 
For each trial type, the following hypotheses were investigated. 
 
Target Trials 
All the labels in the monochrome condition look identical to each other than the 
information on the labels.  Therefore, it would be necessary to read the drug name 
and the strength on most of the labels to identify a target drug in the monochrome 
condition even after getting familiar with the drugs.  In contrast, after getting familiar 
with the drugs, participants in the SCC condition would be able to use colour of the 
labels to differentiate the products of different strengths within the same drug type.  
Also, participants in the existing condition would be able to use the colour scheme of a 
label to identify a specific drug and just read the labels for verification after they 
become familiar with the labels.  It is expected that at least two target trials asking for 
the same label are necessary to allow participants in the SCC condition and the existing 
condition to familiarize themselves with the labels so that they can utilize the label 
colours effectively.  Therefore, it is hypothesized that participants would take the 
longest period of time to find the target drug labels when they are asked the same 
target labels for the third time in the monochrome condition, a shorter period of time in 
the SCC condition and the shortest period of time in the existing condition. 
 
Hypothesis 1: The average response time for the third target trials will be the longest 




After getting familiar with the location of the target labels, participants are expected to 
look at the expected location first when searching for the target labels. When two 
products of the same drug type are misplaced at the place of each other, participants are 
expected to sometimes fail to recognize the misplacement error unless there are salient 
differences in the look of the two products, and the labels are carefully read at all times.  
Even if participants notice the error, it is likely to take them longer to find the correct 
label than it takes to find the label in the target trials due to their expectation.  Since 
all the labels look identical to each other in the monochrome condition, participants in 
this condition are likely to take longer to identify the error and find the target label or 
more likely to fail to recognize the error due to expectancy-based perceptual confusion 
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compared to participants in other colour conditions.  In the existing condition, each 
label is given a unique colour scheme, and therefore it will be relatively easy to 
recognize that some drugs are misplaced.  Since each label within the same drug type 
is given a unique colour in the SCC condition, participants assigned to this condition 
are expected to recognize the misplaced drugs within the same drug type as easily as in 
the existing condition. 
 
Hypothesis 2: The response time for the location foil trials will be longer than the 
average response time for the target trials regardless of colour condition. 
 
Hypothesis 3: The average response time of participants for the location-foil trials will 
be longer in the monochrome condition compared to the SCC condition and the 
existing condition. 
 
Hypothesis 4: The accuracy of participants for the location-foil trials will be low in the 
monochrome condition compared to the SCC condition and the existing condition. 
 
Name-foil Trials 
When a drug with a LASA name as the target drug name is placed where the target 
drug is supposed to be located, and when the two labels look-alike, people will 
sometimes fail to recognize the difference between the two drugs and select the wrong 
drug.  Participants in the existing condition are expected to be most likely to 
misperceive the name-foil labels as the target labels since they would be able to set a 
strong expectation about the drug identity by using the colours of the labels alone and 
therefore would be vulnerable to expectancy-based perceptual confusion.  For 
participants in the SCC condition, it should be obvious to them that there are multiple 
drugs that share the same colours.  Therefore, participants would not be able to 
develop expectations about the drug identity based on the colour of the labels alone 
before reading the labels as would be the case for participants in the monochrome 
condition.  Nevertheless, since participants are not aware of when they would 
encounter the name-foil labels, their expectation that the target label exists in the 
display would likely make them still somewhat vulnerable to expectancy-based 
perceptual confusion and lead them to sometimes misperceive the LASA names as the 
target drug names.  Even when participants do not fall prey to the expectancy-based 
perceptual confusion, participants are expected to take longer to identify the 
unexpected name-foil label than to identify the target label in the target trials as 
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illustrated by the longer response times observed in the study by Martens (2004) when 
a visual target appeared when participants did not expect it compared to when it was 
expected. 
 
Hypothesis 5: The accuracy of participants for the name-foil trials in the existing 
condition will be lower than that in the monochrome condition and that in the SCC 
condition. 
 
Hypothesis 6: The average response time for the name-foil trials will be longer than 
that for the target trials. 
 
Hypothesis 7: The accuracy of participants for the name-foil trials in the monochrome 
condition and that in the SCC condition will be close to each other. 
 
Hypothesis 8: The overall accuracy for the name-foil trials would be lower than that 







The participants, the materials, the experimental design, the procedure and the 
dependent measures are discussed in this chapter.  The materials include the vision 
testing tools, the equipments and the different types of the label prototypes that were 
used as the stimuli.  For the experimental design, the statistical design of the 
experiment including the factors involved, randomization and the counter-balancing 
schemes are described.  For the procedure, the detailed steps that participants 
followed are described.    
 
4.1 Participants 
Thirty-six undergraduate and graduate students from the University of Waterloo 
participated in the study.  Participants consisted of 21 males and 15 females, with age 
ranging from 18 to 34 (M = 24).  None of participants had any experience working at 
a pharmacy.  Participation was voluntary, and participants were remunerated at a rate 
of $5 per half an hour.  Each participant was randomly assigned to one of the colour 
conditions (i.e. 12 participants per each colour condition).  Participants were required 
to have a normal or corrected-to-normal near-vision acuity of 20/40 or better and 
normal colour vision. 
 
4.2 Materials 
The Waterloo Near Vision Test card was used for measuring participants’ near-vision 
acuity, and the Ishihara Pseudoisochromatic Plates (38 plate version) were used for 
examining participants’ colour vision.  The visual search tasks were conducted using 
a Pentium D, 3.4 GHz, Windows XP Professional personal computer with 2.0 GB of 
RAM.  The stimuli for the tasks were displayed on a 22-inch LCD monitor with a 
1680 x 1050 resolution.   
 
 A set of standardized labels were developed for a previous phase of the study 
that this study is part of.  The labels were standardized based on the CSA standard 
with some modifications.  The common name of the drug, the amount of drug 
ingredient(s) as mg per 1 mL and per total mL as well as the routes of administration 
were printed in black characters on a white background.  The addition of routes of 
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administration to the critical information field was based on the finding from a 
previous phase of the study that users perceive routes of administration as one of the 
most important pieces of information on injectable drug labels (Jeon, Hyland, Burns, & 
Momtahan, 2007).  Except for the expiry date, the lot number and the manufacturer 
name, the non-critical information was printed in black characters on a grey 
background.  All the standardized labels looked identical to each other sharing the 
same type size, style, spacing between lines of text, etc. 
 
4.2.1 All conditions 
Utilizing the standardized label prototypes for 5 mL vials, labels for 12 different drugs 
were developed in three different colour conditions: monochrome, existing and SCC.  
Regardless of colour condition, all the labels displayed the common name of the drug 
and the routes of administration in black characters on a white background.  The drug 
strength field was printed with a different background colour (and with a different type 
colour whenever necessary to provide sufficient contrast, description to follow) from 
those used for displaying the common name and the routes of administration, 
following the common method of highlighting drug strength on the existing LSVSV as 
discussed above.  Considering the fact that only a portion of the label is visible when 
it is wrapped around on a small-volume ampoule or vial, highlighting drug strength in 
this manner was also considered to be an effective method for differentiating or 
emphasizing drug strength in the real world scenario.  To ensure that the effects from 
highlighting drug strength does not confound with colour condition, a light grey was 
chosen as the background colour for drug strength in the monochrome condition. 
 
4.2.2 Existing condition 
For the existing condition, 24 different background colour schemes used for the 
LSVAV from a major manufacturer of injectable drugs were selected.  Then, the 
colours were mapped to the closest Pantone® colours (uncoated), and the resulting 
Pantone® colour schemes were used as the background colours for the drug strength 
and the non-critical information (see Appendix A for the Pantone® colours used for the 
label prototypes).  The default type colour was black.  However, when a background 
colour was relatively dark and did not provide sufficient contrast with type in black, 
white was used as the type colour.  This was to ensure that the legibility of the labels 
do not confound with colour condition.  The colour schemes were randomly assigned 
to the label prototypes such that no similar colour schemes were shared by two or more 
labels within each stimuli set (description to follow).   
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4.2.3 Strength Colour Coding Condition 
For the SCC condition, red, yellow, blue and grey Pantone® colours (uncoated) from 
the international colour coding system for syringes in anaesthesia were selected (Royal 
College of Anaesthetists, 2003).  The colours were selected to ensure maximal 
difference across the three colours in terms of hue, saturation and brightness.  The 
colours are also not affected by the most common type of colour blindness involving 
red and green.  The grey was used to code drugs that have only one strength level 
(herein called NSL-1 drugs).  The blue was used to code the lowest strength level of 
drugs that have two or three strength levels (herein called NSL-2 drugs and NSL-3 
drugs, respectively).  The yellow was used to code the second highest strength level 
of NSL-3 drugs.  Finally, the red was used to code the highest strength level of NSL-2 
and NSL-3 drugs.  Table 2 illustrates the SCC system.  All the information on the 
labels in the SCC condition was printed in black. 
 
Number of strength 
levels (NSL) 
Low Medium High 
1 Grey N/A N/A 
2 Blue N/A Red 
3 Blue Yellow Red 
Table 2: Strength colour coding system 
   
4.2.4 Drug names and strengths 
Twelve drug names were selected from the list of confused drug names compiled by 
the ISMP and from the list of drug names from the FDA’s Name Differentiation Project 
(Institute for Safe Medication Practices, 2006a; US Food and Drug Administration, 
2002).  The selected drug names were generic names of three or four syllables in 
length and started with a different letter.  The drug names were divided into four 
stimuli sets consisting three drug types each in an alphabetical order such that each 
stimuli set (SS) consisted of drugs that are likely to be stored in close proximity to each 
other.  One of the drugs in each group was assigned to be a NSL-1 drug, another drug 
to be a NSL-2 drug and the remaining drug to be a NSL-3 drug.  Therefore, each SS 
contained six labels; one label for a NSL-1 drug, two labels for a NSL-2 drug and three 
labels for a NSL-3 drug.  Within each SS, one NSL-1 drug label and two NSL-2 drug 
labels were arranged together in one row, and three NSL-3 drug labels were arranged 
together in the other row.  Within each drug type, the labels were arranged in 
increasing strength levels from left to right (except in the location-foil condition, 
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description to follow).  Therefore, each SS displayed six labels in two rows of three 
labels.  Figure 11 shows a sample SS in the three colour conditions. 
 
 The lowest strength level for all drugs within each SS had the same 
concentration value.  The concentration values were selected randomly with a 
constraint that the highest strength level of a NSL-2 drug, and the medium and the 
highest strength level of a NSL-3 drug do not share the same values.  Each label 
displayed the total volume of the container, a pseudo Drug Identification Number, the 
common name of the drug, the drug strength in mg per mL and in mg per total mL, the 
routes of administration, the storage condition, a pseudo lot number, the text indicating 
sterility, the text indicating single-use, the manufacturer name, the expiry date and a 
pseudo barcode.  See Appendix A for more detailed information displayed on the 
labels.  Franklin Gothic Medium was the font type for all the pieces of information on 
the labels.  Due to the limited resolution of the monitor, the label prototypes were 
enlarged by 20 % from the actual label size for 5 mL vials to ensure that the text on the 
label prototypes is clearly legible on the monitor.  Each label subtended a visual angle 
of 4.3° in width and 9.0° in height, and the labels were separated from each other by 
2.9°.   
 




Figure 11 (continued): A sample stimuli set in the existing condition (bottom), and in the 
SCC condition (top) 
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4.3 Experimental Design 
The experiment was of a mixed-model design.  The between-subject factor was 
colour condition (three levels: monochrome, existing and SCC).  The within-subject 
factors were SS (four levels: 1, 2, 3, 4), NSL (three levels: NSL-1, NSL-2 and NSL-3), 
drug type (12 levels) and trial type (five levels: first, second & third target trials, one 
name-foil trial and one location-foil trial per drug type).  There were five trials for 
each NSL-2 and NSL-3 drug and four trials for each NSL-1 drug (since there was no 
location-foil trials for the NSL-1 drugs), resulting in a total of 56 trials for each 
participant in the experimental session. 
 
 In the target trials, a label that matches the target drug name and the strength 
existed in the SS.  There were three target trials for each target label.  In the name-
foil trials, the target label was replaced with a label for a different drug with a LASA 
generic name as the target drug name while everything else about the label was 
identical to the target drug label.  The LASA name was the one paired with each 
target drug name in the list of confused drug names from the ISMP or the FDA’s Name 
Differentiation Project.  Table 3 shows the pairs of the target drug name and the 
LASA name used in the study, and Figure 12 shows a sample pair of a target drug label 
and a name-foil label.  In the location-foil trials, the location of the target drug label 
was swapped with the location of a label of the same drug but of a different strength.  
 
 For each SS, there were four possible ways to arrange the labels.  The four 
arrangement schemes were assigned to the SSs using a four by four balanced Latin 
Square such that the assignments were counter-balanced across four participant groups 
(three participants per group) as shown in Table 4.  The same assignment scheme was 
used across the colour conditions. 
 
 For NSL-2 and NSL-3 drugs, one of the strength levels was chosen as a target 
in a random manner across 12 participants per each colour condition.  Also, for each 
NSL-3 drug, the strength level of the drug of which label location was to be swapped 
with the target label location in the location-foil condition was selected in a random 
manner across 12 participants per each colour condition.   The same randomized 




Stimuli Set Target Drug Name LASA Name 
1 Bupropion* Buspirone* 
1 Cisplatin Carboplatin 
1 Dopamine* Dobutamine* 
2 Ephedrine Epinephrine 
2 Glipizide* Glyburide* 
2 Hydralazine* Hydroxyzine* 
3 Lamivudine Lamotrigine 
3 Methimazole Metolazone 
3 Nicardipine* Nifedipine* 
4 Prednisone* Prednisolone* 
4 Tolazamide* Tolbutamide* 
4 Vinblastine* Vincristine* 
Table 3: Target drug name and LASA name pairs 
* from the FDA’s Name Differentiation Project, and the rest from the ISMP’s List of Confused 
Drug Names 
  
   
Figure 12: A sample pair of the target drug label (left) and the name-foil label (right) in 
the monochrome condition 
 
 Arrangement 1 Arrangement 2 Arrangement 3 Arrangement 4 
Group 1 SS-1 SS-4 SS-3 SS-2 
Group 2 SS-2 SS-1 SS-4 SS-3 
Group 3 SS-3 SS-2 SS-1 SS-4 
Group 4 SS-4 SS-3 SS-2 SS-1 
Table 4: Label arrangement and SS assignment counter-balancing scheme 
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 Twelve randomized order of 56 trials were applied to each colour condition.  
The orders were randomized with the constraints that the first foil trial (whether it be a 
location-foil or a name-foil trial) is preceded by at least two target trials and that no 
two consecutive trials have the same target label.  The first constraint was to ensure 
that participants are given a chance to familiarize themselves with the labels before the 




Participants read the information letter, signed the consent form (see Appendix B) and 
completed the background questionnaire (see Appendix C ) that asked their age, gender, 
discipline, handedness and any experience working at a pharmacy.  Then, vision 
testing was conducted to ensure that each participant had the required level of normal 
or corrected-to-normal near-vision acuity and normal colour vision. 
 
 For the visual search tasks, each participant was seated at approximately 40 
cm away from the monitor screen.  The experimenter described the visual search task 
(see Appendix D for the testing protocol).  A target drug name and strength were 
displayed on the monitor for five seconds for each trial.  After five seconds, a SS was 
displayed.  The task goal was to find the label that corresponds to the target drug 
name and the strength and input a response using a numeric key as accurately and as 
fast as possible.  Each label in a SS was mapped to one of the keys from four to nine 
of the numeric keypad based on the label’s position as shown in Figure 13.  
Participants were told to press the zero key on the numeric keypad if they could not 
find a label that matches the target drug name and the strength.  Therefore, the correct 
response for the name-foil trials was always the zero key.  Participants were given as 
much time as needed to input their response.  Upon pressing a key, the screen 
displayed another drug name and strength pair for the next trial.  Figure 14 shows the 
sequence of events.  When participants inadvertently pressed a key that was not 
relevant to the study, a window was displayed informing that a wrong key was pressed.  
Participants were told to press the ‘Enter’ key to close the window, and then input their 
response using a correct key.  For participants assigned to the SCC condition, the 












Figure 13: Labels to numeric key mapping scheme 
   
 Participants were given seven practice trials to familiarize themselves with 
the visual search task and to ask any question they may have.  For the practice trials, a 
SS consisting of three different types of drugs (one NSL-1 drug, one NSL-2 drug and 
one NSL-3 drug) just like the SSs used in the experimental session was used.  The 
drug names and the strengths were different from the ones used for the experimental 
session, although the way colour was applied to the labels was the same as the one 
assigned to each participant.  For the practice trials in the existing condition, six 
random colours that were not used for the labels in the experimental session were 
applied to the labels.  Each label in the SS was asked as the target label once (six 
trials), and one of the drugs with a wrong strength was the target once (one trial).  
Therefore, the practice trials allowed participants to practice using all the numeric keys 
used in the experimental session.  
 
 Throughout both the practice session and the experimental session, the 
experimenter sat behind each participant to observe and make any necessary notes.  
After completing all 56 trials in the experimental session, participants were debriefed 
and given a chance to ask any questions.  The entire session including the vision 









7 8 9 
4 5 6 
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Figure 14: The sequence of events for the visual search task 
 
4.5 Dependent Measures 
The response time to complete each visual task trial (i.e. amount of time from when the 
SS was displayed to when a numeric key was pressed) was logged via a computer 
application as well as the accuracy of the responses. 
Target drug name and 
strength displayed for 5 
seconds 
 
Stimuli set displayed 





The performance on the visual search task was analyzed in terms of the response time 
and the accuracy.  Two observations where participants were confused and required 
the experimenter’s help were considered as outliers and excluded from the analysis 
(one observation was the first trial, and the other was the second trial for the 
corresponding participants).  Therefore, 2014 observations out of a total of 2016 
observations were analysed.  For the response time, the results of analyses of variance 
(ANOVAs) for each trial type and descriptive analysis of all trial types are presented.  
For the response accuracy, the descriptive analysis for all trial types as well as the 
results of an ANOVA and chi-square statistics for the name-foil trials are presented.   
 
5.1 Response Time 
The response time measurements for only the correct responses were analyzed.  Also, 
four observations where participants pressed a key that was not relevant to the task by 
mistake were excluded from the response time analysis.  Therefore, 1820 
measurements out of 2014 measurements were analyzed.  Since the response time 
measurements were positively skewed, log transformed response times were used for 
the mixed-model ANOVAs to conform to the method’s assumption of normal 
distribution. An alpha of 0.05 was used as the significance level unless otherwise noted.  
The results of the statistical analyses on the response times for each trial type are 
summarized in Table 5. 
 
 For the target trials, a three (colour condition: monochrome, existing, SCC) x 
four (SS: SS-1, SS-2, SS-3, SS-4) x three (NSL: NSL-1, NSL-2, NSL-3) x three (order: 
first, second, third) mixed-model ANOVA was conducted (with all the factors 
following the first factor as repeated measures factors).  There was no significant 
main effect of colour condition on the mean response times (F2, 33 = 0.28, p = 0.7573).  
There was a significant main effect of the order of the target trials (F2 66 = 6.73, p = 
0.0022) and of SS (F3, 99 = 10.12, p < .0001).  A post-hoc analysis using Tukey's 
Studentized Range test (α = 0.05) showed that participants responded faster when they 
were asked the same target label for the second (M = 3025 ms, SD = 1438 ms) and the 
third time (M = 3021 ms, SD = 1313 ms) than when asked for the first time (M = 3207 
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ms, SD = 1333 ms).  There was no significant difference between the second and the 
third target trials.  Figure 15 shows the average response times across the three target 
trials for each SS.  The same type of post-hoc analysis for SS showed that it took 
participants significantly longer to find the target labels in SS-3 (M = 3170 ms, SD = 
1267 ms) and SS-4 (M = 3230 ms, SD = 1541 ms) compared to SS-1 (M = 2934 ms, 












M 3309 3143 3165 3207 1st target 
SD 1270 1186 1526 1333 
N/A 
M 3089 3014 2973 3025 2nd target 
SD 1388 1107 1744 1438 
N/A 
M 3138 3055 2871 3021 3rd target 
SD 1357 1435 1127 1313 
SS 
SS, trial order 
and drug type
M 
4134 4514 4636 4422 
Name-foil 
SD 
1326 1437 1823 1556 
SS, NSL, SS x NSL, drug 
type, trial type and drug 
type x trial type (name-foil 
vs. mean target) 
M 3333 3157 3194 3228 Location-
foil SD 1417 1230 1325 1323 
none 
Table 5: Summary of mean correct response times in milliseconds 
 
 The response times for only the third target trials were also analyzed using a 
three (colour condition: monochrome, existing, SCC) x four (SS: SS-1, SS-2, SS-3, 
SS-4) x three (NSL: NSL-1, NSL-2, NSL-3) mixed-model ANOVA (with SS and NSL 
as repeated measures factors).  The main effect of colour condition was not 
significant (F2, 33 = 0.22, p = 0.8000).  The only significant effect was SS (F3, 99 = 4.77, 
p = 0.0038).  Tukey's Studentized Range test (α = 0.05) revealed that the mean 
response time difference between SS-1 (M = 3207 ms, SD = 1317 ms) and SS-3 (M = 
2850 ms, SD = 1171 ms) was significant.  The differences between the other SS pairs 
were not significant.  A closer examination of the two stimuli sets revealed that the 
length of the drug names in SS-1 (eight to nine characters) was shorter than those in 
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SS-3 (ten to 11 characters).  Furthermore, the concentrations of the drugs in SS-1 
were of one digit (for the lowest strength level) or two digits (for higher strength 
levels) while all the concentrations in SS-3 were of two digits.  The shorter length of 
the drug names and the larger visual differences amongst the concentration values 

























Figure 15: Correct mean response times for the three target trials across the stimuli sets1 
  
 For the name-foil trials, a three (colour condition: monochrome, existing, 
SCC) x four (SS: SS-1, SS-2, SS-3, SS-4) x three (NSL: NSL-1, NSL-2, NSL-3) 
mixed-model ANOVA was conducted (with SS and NSL as repeated measures factors).  
The main effect of colour condition was not significant (F2, 33 = 0.37, p = 0.6942).  
There were significant main effects of SS (F3, 90 = 7.14, p = 0.0002) and of NSL (F2, 59 = 
21.96, p < .0001) as well as their interaction effect (F6, 100 = 7.76, p < .0001).  Since 
only the correct responses were analyzed, the dataset was unbalanced, and therefore a 
post-hoc analysis could not be done for the interaction effect.  As shown in Figure 16, 
the response times for NSL-3 targets (M = 5000 ms, SD = 1580 ms) were longer than 
NSL-1 (M = 3985 ms, SD = 1601 ms) and NSL-2 targets (M = 4284 ms, SD = 1356 
ms) across the SSs.  This trend is reasonable since, when participants noticed that the 
foil label was not the target label, they would have searched through the other labels of 
different strengths of the same drug type to ensure that the target label did not exist.  
Since there were more labels to check for NSL-3 targets than for NSL-1 and NSL-2 
                                                     
1 The error bars of the bar graphs in this thesis indicate standard deviations. 
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targets, it would have taken participants the longest to complete NSL-3 name-foil trials 
compared to those involving the other NSL type targets.  However, the trend and the 
degree of the mean response time difference between NSL-1 and NSL-2 targets 
differed across the SSs.  Since drug type differed across the NSLs and across the SSs, 
and since the degree of similarity between each pair of the target drug name and LASA 
name was not controlled, it was suspected that the interaction effect could be due to the 
differences amongst the individual drugs.  Therefore, a three (colour condition: 
monochrome, existing, SCC) x 12 (drug type) mixed-model ANOVA was conducted 
(with drug type as repeated measures factor).  As suspected, there was a significant 
main effect of drug type (F11, 252 = 13.28, p < .0001, M = 4422 ms, SD = 1556 ms).  



























Figure 16: Correct mean response times for the name-foil trials across stimuli set & NSL 
levels 
  
 The response times for the name-foil trials were compared to the 
corresponding average response times across the three target trials using a three (colour 
condition: monochrome, existing, SCC) x 12 (drug type) x two (trial type: name-foil, 
mean of target trials) mixed-model ANOVA.  There were significant main effects of 
drug type (F11, 363 = 10.60, p < .0001) and trial type (F1, 33 = 161.17, p < .0001) as well 
as their interaction (F11, 252 = 6.24, p < .0001) as shown in Figure 17.  The mean 
response time for the name-foil trials (M = 4422 ms, SD = 1556 ms) for every target 
drug type was longer than the average response time for the target trials for that target 
drug type (M = 3095 ms, SD = 1094 ms) while the degree of difference differed across 
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the target drug types.  The interaction effect was reasonable since the degree of 
similarity between each pair of target drug name and LASA name was not controlled.  
Also, it is likely that the response time increased with the increasing number of 
strength levels for the reasons discussed above. 
 
 For the location-foil trials, a three (colour condition: monochrome, existing, 
SCC) x four (SS: SS-1, SS-2, SS-3, SS-4) x two (NSL: NSL-2, NSL-3) mixed-model 
ANOVA was conducted (with SS and NSL as repeated measures).  There were no 
significant main effects or interaction effects.  A three (colour condition: 
monochrome, existing, SCC) x 12 (drug type) mixed-model ANOVA did not reveal 
any significant effect either.  The response times for the location-foil trials were 
compared to the corresponding average response times across the three target trials 
using a three (colour condition: monochrome, existing, SCC) x 12 (drug type) x two 
(trial type: location-foil, mean of target trials) mixed-model ANOVA.  The main 


























Figure 17: Mean correct response times for each drug type for the name-foil trials and the 
























Figure 18: Mean correct response times for each drug type for the location-foil trials and 
that for the average of the target trials 
 
5.2 Response Accuracy 
For each trial type, the mean accuracies of the responses for individual participant were 
computed and compared across the colour conditions as summarized in Table 6.  The 
accuracy was defined as a percentage of the correct responses.  The mean accuracy 
for the target trials was high for all the colour conditions with small variations across 
participants (M = 94.9 %, SD = 4.6 %, averaged across the colour conditions).  The 
result was not surprising since participants were given as much time as needed to 
complete their tasks.  Similarly, the mean accuracy for the location-foil trials was 
very high for all the colour conditions (M = 95.5 %, SD = 8.0 %, averaged across the 
colour conditions).  In fact, the mean accuracy for the location-foil trials was 
approximately equivalent to that of the target trials.  Except for one participant in the 
SCC condition (accuracy of 62.5 %), all participants either correctly identified all the 
targets in the location-foil trials or misidentified one target only.  It is not clear why 
the particular participant did poorly on the location-foil trials (the participant’s 
accuracy was 97 % and 92 % for the target trials and for the name-foil trials, 










Mean Median Minimum Maximum SD 
Monochrome 95.4 95.8  83.3  100.0  5.1  
Existing 93.7 94.4  83.3  100.0  5.0  
SCC 95.6 97.2  88.9  100.0  3.8  
Target 
Average 94.9 95.8  83.3  100.0  4.6  
Monochrome 78.5 83.3  33.3  100.0  18.3 
Existing 68.1 75.0  16.7  91.7  22.1 
SCC 76.4 83.3  8.3  91.7  24.1 
Name-
foil 
Average 74.3 83.3  8.3  100.0  21.5 
Monochrome 95.8 100.0  87.5  100.0  6.2  
Existing 96.9 100.0  87.5  100.0  5.7  
SCC 93.8 100.0  62.5  100.0  11.3 
Location-
foil 
Average 95.5 100.0  62.5  100.0  8.0  
Table 6: Summary of mean percentage accuracies  
 
 The accuracy of the name-foil trials was analyzed by using participant 
accuracies collapsed across the drug types.  The accuracy for the target-trials per each 
participant averaged across the drug types was also calculated to compare to the 
accuracy of the name-foil trials.  The participants’ accuracy for the name-foil trials 
and the target trials were analyzed using a two (trial type: name-foil, target) x three 
(colour condition: monochrome, existing, SCC) mixed-model ANOVA with colour 
condition as a repeated measure factor.  The main effect of colour condition was not 
significant (F2, 33 = 0.92, p = 0.4103) as well as the interaction of trial type and colour 
condition (F2, 33 = 0.58, p = 0.5644).  The main effect of trial type was significant (F1, 
33 = 35.70, p < .0001).  The mean accuracy of the name-foil trials (M = 74.3 %, SD = 
21.5 %) was significantly lower than that of the target trials (M = 94.9 %, SD = 4.6 %).  






















Figure 19: Mean accuracy of the name-foil and the target trials for each colour condition 
 
 Although the difference in accuracy across the colour conditions for the 
name-foil trials was not significant using the ANOVA, the trend was consistent with 
the prediction of Hypothesis 7; 78.5 % for the monochrome condition, 68.1 % for the 
existing condition and 76.4 % for the SCC condition.  Given the relatively large 
differences in the mean accuracies of participants for the name-foil trials as shown in 
Table 6, the name-foil accuracy was further analyzed by categorizing participants in 
terms of their performance using the median accuracy of 83.3 % as the threshold; 
‘pass’ (if the mean accuracy is greater than or equal to the median) or ‘fail’ (if less than 
the median).  The frequencies of participants who passed or failed the task were 
analyzed using a three (colour condition: monochrome, existing, SCC) by two 
(success: pass or fail) two-way frequency table as shown in Table 7.  The association 
between colour condition and success on the name-foil trials was marginally 
significant (likelihood ratio chi-square value = 5.7467, d.f. = 2, p = 0.0565).  In the 
existing condition, there were three times as many participants who failed the task as 
those who passed.  In contrast, there were twice as many participants who passed the 
task as those who failed in both the monochrome condition and the SCC condition.  
Hypothesis 2 predicted that the accuracy of participants in the existing condition would 
be lower compared to both the monochrome condition and the SCC condition.  Also, 
as shown in Table 7, the frequencies of participants who passed or failed the task were 
identical in both the monochrome condition and the SCC condition.  Therefore, the 
two conditions were grouped together, and the probability of success and its 
association with colour condition was observed using a two (colour condition: existing, 
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monochrome/SCC) by two (success: pass or fail) two-way frequency table.  The 
association between the colour condition and the frequency of success were 
significantly associated (Fisher’s exact test, two-sided p = 0.0328).  Due to the limited 
number of observations, the accuracy data could not be statistically analyzed across the 
drug types reliably. 
 
Colour condition Fail Pass Total 
Monochrome 4 (33.3%) 8 (66.7%) 12 
Existing 9 (75.0%) 3 (25.0%) 12 
SCC 4 (33.3%) 8 (66.7%) 12 
Total 17 (47.2%) 19 (52.8%) 36 
Table 7: Table of frequencies of participants who passed or failed the name-foil trials 
 
 For the above accuracy analysis of the name-foil trials, nine observations 
where a label other than the foil label was selected were counted towards the number 
of inaccurate trials.  It is likely that participants forgot the target drug name and/or 
strength in these trials.  Therefore, it is difficult to say that participants read the foil 
labels and perceived them as the target labels.  Since the focus of interest was the 
likelihood of perceiving the foil labels as the target labels when the foil labels were 
read, the data excluding the nine observations were further analyzed.  The average 
rate of perceiving the foil labels as the target labels for each participant was calculated.  
Then, the median rate of 16.7 % was used to categorize each participant as ‘pass’ (if 
the rate is less than or equal to the median) or ‘fail’ (if greater than the median).  The 
resulting three (colour condition: monochrome, existing, SCC) by two (success: pass 
or fail) two-way frequency table was identical to Table 7.  Therefore, the association 
between colour condition and the frequencies of selecting the foil labels as the target 
labels (across all three colour conditions as well as after grouping the monochrome 
condition and the SCC condition together) had the same significance level as in the 





The results of the experiment for each trial type are examined with respect to the 
corresponding hypotheses.  The results are further discussed in context of the work of 
healthcare professionals and standardization of injectable drug labels.  Based on the 
findings, general recommendations for minimizing the occurrence of medication errors 
involving labelling and packaging are suggested.  
 
6.1 Target trials 
Hypothesis 1: The average response time for the third target trials will be the longest 
in the monochrome condition, shorter in the SCC condition and the shortest in the 
existing condition. 
 
The mean correct response times for all the target trials as well as for the third target 
trials alone were not significantly different across the colour conditions, rejecting 
Hypothesis 1.  There are several potential reasons for this result.  First of all, the 
high legibility of the labels in all the colour conditions may have produced a ceiling 
effect.  It was ensured that all the labels had a sufficient contrast between the 
characters and the background.  Moreover, the labels were displayed on a monitor, 
and therefore a high luminance level was ensured.  Since the labels were easy to read, 
participants may not have found a need to use colour in the existing condition or in the 
SCC condition.  Secondly, it is possible that two target trials were not enough for 
participants to sufficiently familiarize themselves with the drugs and the number of 
strength levels available for each drug in order to utilize the SCC system effectively.  
For the same reason, participants in the existing condition may not have established a 
mental association between the colour of the label and each drug.  Finally, 
participants could have been motivated to read the labels very carefully as they 
encountered the location-foil trials and the name-foil trials before some of the third 
target trials.  Also the fact that participants were not familiar with the task of 





6.2 Location-foil trials 
Hypothesis 2: The response time for the location foil trials will be longer than the 
average response time for the target trials regardless of colour condition. 
 
Hypothesis 3: The average response time of participants for the location-foil trials will 
be longer in the monochrome condition compared to the SCC condition and the 
existing condition. 
 
Hypothesis 4: The accuracy of participants for the location-foil trials will be low in the 
monochrome condition compared to the SCC condition and the existing condition. 
 
There was no significant difference in the response time or in accuracy for the 
location-foil trials across the colour conditions, contrary to the predictions of 
Hypothesis 2, 3 and 4.  The results may also illustrate the ceiling effect.  Most 
participants were rarely confused by the location-foil trials regardless of the colour 
condition they were assigned to.  In fact, the median accuracy across the colour 
conditions was 100 %, and the mean accuracy was approximately equal to that of the 
target trials.  Given the high legibility of the labels, the misplaced labels could have 
been too obvious for participants to be affected by different ways of using colour.   
 
6.3 Name-foil trials 
Hypothesis 5: The accuracy of participants for the name-foil trials in the existing 
condition will be lower than that in the monochrome condition and that in the SCC 
condition. 
 
Hypothesis 6: The average response time for the name-foil trials will be longer than 
that for the target trials. 
 
The trends in the response times and the accuracy for the name-foil trials were 
consistent with the predictions of Hypothesis 5 and 6.  Overall, the accuracy for the 
name-foil trials was significantly lower than that for the target trials regardless of the 
colour conditions.  The difference in accuracy was as predicted by Hypothesis 5.  
Moreover, when participants correctly recognized that a name-foil label was presented 
in place of an expected target label, it took them significantly longer to recognize the 
error and input a response compared to when they were asked for the same drug in the 
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target trials, consistent with the prediction of Hypothesis 6.  The low accuracy and 
long response time for the name-foil trials occurred even though the legibility of the 
drug names was ensured on every label as they were printed in black characters on a 
white background as well as following the legibility requirements of the CSA standard 
(Section 4.4, Canadian Standards Association, 1999).  Clearly, a high level of 
legibility alone was not sufficient to prevent people from selecting a wrong drug with a 
LASA name regardless of how colour is used on the labels.  The trends in the 
response times and the accuracy for the name-foil trials suggest that people are in 
general very vulnerable to confusions from LASA drug names when the problem is 
compounded by similarity in the look of the labels. 
 
Hypothesis 7: The accuracy of participants for the name-foil trials in the monochrome 
condition and that in the SCC condition will be close to each other. 
 
Hypothesis 8: The overall accuracy for the name-foil trials would be lower than that 
for the target trials regardless of the colour condition. 
 
 How colour is used on the labels also had a significant effect on the accuracy 
of the name-foil trials although the significance of the result is limited due to the 
relatively small number of observations.  The mean accuracy of participants for the 
name-foil trials in the existing condition was lower than that in the monochrome 
condition and that in the SCC condition as predicted by Hypothesis 7.  While more 
participants differentiated the name-foil labels from the target labels with relative 
success than those who did not in the monochrome and the SCC condition, the trend 
was reversed in the existing condition.  Also, the relative success of participants on 
the name-foil trials for the monochrome condition and for the SCC condition was not 
significantly different from each other, partially supporting Hypothesis 8.   In the 
existing condition, there was an approximate one-to-one relationship between the drug 
identity and the colour scheme of a label while there was no such one-to-one 
relationship for the labels in the monochrome condition and in the SCC condition.  
Therefore, participants in the existing condition might have developed a strong 
expectation about the identity of a drug when they perceived the colours of the label, 
especially since there were no other visually distinguishable variables other than the 
label content and colour.  People’s tendency to perceive stimuli in a manner such that 
it is consistent with their expectation especially when the actual stimuli and the 
expected stimuli are look-alike seems to have made participants in the existing 
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condition more prone to misperceive the name-foil labels as the target labels compared 
to other colour conditions.  It is possible, however, that the similar performance level 
of participants in the SCC condition and those in the monochrome condition resulted 
from participants in the SCC condition mostly disregarding the colour coding system 
rather than participants not associating the colour scheme of a label to a specific drug.  
As discussed above, the high legibility of the labels may have produced a ceiling effect, 
and therefore participants in the SCC condition may not have felt a need to use the 
colour coding system for their task.  Moreover, two to four trials before seeing the 
name-foil labels (since the order in which the third target trial and the foil trials 
appeared was randomized) may not have been sufficient for participants to familiarize 
themselves with the drug types and the number of strengths available for each drug 
type to utilize the colour coding system. 
 
 Although the relative success on the name-foil trials based on accuracy 
differed significantly across the colour conditions, there were no significant differences 
in the response times for the name-foil trials across the colour conditions.  Assuming 
that the length of response time is approximately proportional to how carefully 
participants read the labels, participants in each colour condition all seem to have read 
the labels equally carefully.  Thus, the lower accuracy of participants in the existing 
condition does not seem to have resulted from the particular group of participants not 
reading the labels as carefully as the others.  Rather, the lower accuracy in the 
existing condition may be induced by the expectancy-based perceptual confusion as 
discussed above. 
 
6.4 General discussion 
Healthcare professionals are likely to confuse drugs with look-alike 
labelling/packaging and LASA drug names as the intended drugs than participants in 
this experiment given their work environment and experience that create a situation 
prone to expectancy-based perceptual confusion.  Participants in the experiment did 
not have prior knowledge of the drug names nor injectable drug labels and only saw 
the same target drug labels two to four times before seeing the name-foil labels.  
Therefore, it is likely that participants did not rely on their memory to complete their 
tasks; i.e. they did not use colour extensively to identify the target drug labels.  The 
fact that there were no significant differences in both the response times and the 
accuracies across the colour conditions in the target trials and in the location-foil trials 
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adds support to this prediction.  Furthermore, only one out of eight participants in the 
existing condition commented that she used colour as a means of identifying the target 
drug labels.  On the contrary, experienced healthcare professionals are very familiar 
with a set of drugs that they use frequently including their storage location, the look of 
their containers and the drug names.  Therefore, to experienced healthcare 
professionals, drug identification task is a highly-practiced routine task that is 
performed in a rapid, automatic manner without conscious effort (Cohen, 1999, p. 
13.2).  According to Reason (1990), the more often the task is repeated successfully, 
the more likely that our mind would accept the stimuli input that is look-alike the 
expected stimuli, and therefore the more likely one would fall prey to perceptual 
confusion.  Moreover, healthcare professionals seem to use their knowledge of the 
colours of drug labelling/packaging extensively to identify drugs.  For example, most 
of the anaesthesiologists surveyed by Orser et al. (2001) identified colour as the single 
most important feature to identify drugs.  Therefore, the mental expectation about the 
drug identity that is developed when healthcare professionals see a drug label with a 
seemingly unique colour scheme would be very strong.  Consequently, healthcare 
professionals are expected to be more prone to confuse drugs with look-alike labels 
and/or LASA names. 
 
 Another factor that makes healthcare professionals more vulnerable to 
expectancy-based perceptual confusion is that the work of healthcare professionals is 
laden with interruptions and time-constraints.  Reason (1990) identifies attention 
capture associated with distraction or preoccupation as major environmental factors 
that affect errors at the skill-based level including expectancy-based perceptual 
confusion.  The more the focus of attention is away from the task of interest, the more 
likely that the individual would fail to perform an attentional check on the stimuli.  
Interruption and work overload that can create such attentional capture are prevalent in 
healthcare as they have been identified as the leading contributing factors of 
medication errors.  According to the medication errors reported to the USP’s 
MedMARX program from 1999 to 2003, distraction and workload increase were the 
two most frequently cited contributing factors (44.6 % and 21.5 %, respectively) 
(Hicks, Santell, Cousins, & Williams, 2004).  Beso, Franklin and Barber (2005) 
observed the frequency and the potential causes of dispensing errors at the final check 
stage and outside of a hospital pharmacy in the UK.  The error-producing conditions 
most frequently reported by the dispensary staff members who were involved in the 
identified dispensing errors were being busy, subject to time-constraints, short-staffed 
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and physical condition of the individual.  It is human nature to internalize regularities 
in the world and process familiar information in a rapid manner without conscious 
effort using one’s knowledge such that their limited attentional resources can be freed 
up for other tasks (Reason, 1990, pp. 20, 72).  Considering the hectic nature of the 
work of healthcare professionals and their high level of familiarity with the drugs that 
they handle, healthcare professionals are likely to perform the drug identification task 
more or less automatically using their well-practiced behaviour to minimize load on 
their limited attentional resources.  This is a good adaptive strategy for the cognitive 
system; yet, processing information in this manner increases the likelihood of 
accepting look-alike stimuli as the expected stimuli.  Therefore, if this experiment 
were conducted with healthcare professionals with the drugs that they are familiar with 
and using the colours on the existing labels, there might have been a larger effect of 
colour condition on the labels on their ability to differentiate the name-foil labels from 
the target labels.  
 
 For reducing confusions from LASA drug names, visually differentiating 
LASA drug names by highlighting the sections of names that are different from each 
other by using uppercase letters (called tallman lettering) has been suggested.  As a 
result of the FDA’s Name Differentiation Project, the Office of Generic Drugs 
encouraged the manufacturers of drugs with look-alike names to visually differentiate 
the names using tallman lettering (US Food and Drug Administration, 2002).  For 
example, Dobutamine and Dopamine were suggested to be printed as DOBUTamine 
and DOPamine.  Filik, Purdy and Gerrett (2006) showed through three experiments 
that as long as people are aware of the fact that tallman lettering is used for 
differentiating similar drug names, tallman lettering makes similar drug names easier 
to distinguish as well as recognizing a correct drug name easier.  Gabriele (2006) 
went further to explore if an alternative typographical contrast other than tallman 
lettering could be more effective in differentiating LASA drug names.  Three word-
recognition tests were conducted with 11 critical care nurses where they were given a 
list of LASA drug names that used one of the three typographical contrasts: tallman 
lettering, changing medium-weight characters to boldface characters or changing black 
characters to white characters on a solid black rectangle (e.g. HydrOXYzine, 
Hydroxyzine, Hydroxyzine, respectively).  Participants recognized most drugs names 
when the portions of the names were printed in white characters on a black rectangle, 
followed by tallman lettering and boldface characters.  The experiment, however, was 
limited by the small sample size and the artificial nature of the word-recognition tasks.   
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 Currently, the CSA standard does not directly address the issue of LASA drug 
names.  The standard only ensures the legibility of the drug’s common name on an 
individual label.  However, the evidence from this study and from the studies 
discussed above show that a high level of legibility alone is not sufficient to prevent 
confusions from LASA drug names, especially when the problem is confounded by the 
similarity in the look of the drug’s labelling/packaging.  Therefore, incorporating 
appropriate typographical measures such as tallman lettering to help differentiate 
LASA drug names into the standard is recommended to be considered when the 
standard is reviewed for improvement.  
  
 Although the standardized labels using the existing colour schemes in this 
thesis reflect an extreme hypothetical scenario where there is no variation in type font, 
size and spacing, the results show cautions to be taken when attempting to standardize 
the LSVAV following the CSA standard or any other standards.   The manufacturer 
from which the colour schemes for the existing condition were adopted from is a major 
provider of injectable drugs in Canada.  In fact, 60 % of the injectable drug ampoules 
and vials (N = 78) collected for the previous phase of the project to which this thesis 
belongs were from the particular manufacturer.  The manufacturer uses the type 
colours and the background colours of the labels extensively for their injectable drug 
products to differentiate one product from another.   In addition to colour, the 
existing labels are different in terms of several other factors including the alignment of 
text, the type font and the direction of text.  However, when the LSVAV are 
standardized following the CSA standard, the text is required to be printed in a single 
direction.  Also, the critical information field is required to be printed in black 
characters on a white background with lines of text flush with the left margin, with a 
ragged right margin along with other detailed typographical requirements.  Therefore, 
if a manufacturer standardizes all of its LSVAV following the CSA standard without 
sufficient variation in the portions of the labels outside the critical information field 
other than colour, then the products that are currently effectively differentiated may 
produce colour coding effects.  As long as there are differences in the colour schemes 
across a certain set of products that are frequently encountered, users will likely 
associate the colour of each label with a unique drug identity.  Consequently, as 
demonstrated by the relatively low accuracy of participants in the existing condition 
for the name-foil trials, users will become very vulnerable to confusions from look-
alike labels and LASA names due to expectancy-based perceptual confusions.   
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 Ironically, it is desirable that each product has a unique colour scheme in the 
current context.  In fact, healthcare facilities are recommended to purchase products 
from different manufacturers if necessary to ensure that products that have look-alike 
labels (and the look of the labels is largely determined by their colour as illustrated in 
Section 2.5) are not stored in the vicinity of each other.  This may be desirable in the 
current condition since there are many other visual variables of the labels that 
differentiate one product label from another.  However, if the same method of 
applying colour to differentiate products is applied to standardized labels, the resulting 
labels may create an error-prone condition. 
 
 Consistency in layout and high legibility of information critical for the safe 
use of injectable drugs via standardization would help reduce errors from misreading 
the labels.  However, when standardizing the existing labels, care should be given to 
ensure that variations in factors other than colour exist across the labels.  As 
discussed in Chapter 2, colour is limited in many ways to be relied upon as a single 
variable for identifying drugs.  Nevertheless, since colour does not require effortful 
cognitive processing, people are prone to use it as a primary cue for identifying drugs 
in the absence of other distinguishing features and consequently exposing themselves 
to the negative effects of expectancy-based perceptual confusions.   The UK 
Medicines and Healthcare products Regulatory Agency (MHRA) encourages the use of 
“innovative pack design” especially for small container labels where space is at a 
premium in its best practice guideline on labelling and packaging of medicines 
(Medicines and Healthcare products Regulatory Agency, 2003).  As long as such 
innovative designs do not distract users from reading the labels for identifying and 
using the drug safely, they would add to the number of variables that distinguish 
products, and therefore prevent users from relying on colour of the labels excessively 
to identify drugs. 
 
 It is difficult to conclude from this study which method of using colour is 
optimal for the LSVAV to minimize the risk of medication errors.  The study fell short 
of showing that colour can help identify unique drugs or differentiate products of 
different strengths within the same drug type compared to when no colour is used.  
Nevertheless, the limited opportunities for participants to familiarize themselves with 
the drugs and their label colours and the relatively stress-free condition of the 
experimental setting may have made the behaviour of participants significantly 
different from those of healthcare professionals.  Nonetheless, the study illustrates 
 57
that when colour is used on medication labels such that unique colour schemes are 
used for different drugs in most cases without other distinguishable features, people 
can be more likely to fail to differentiate a look-alike label with a LASA name than 
when no colour is used or when colour is used with no apparent one-to-one association 
between a product and its colour scheme.  In the absence of salient features that 
differentiate the look of the labels other than colour, the user is likely to develop a 
strong internal expectation about the drug identity based on the look a label (of which 
colour is a significant factor) when there is a seemingly one-to-one association 
between the colours of labels and drug identity.  The user’s expectation when coupled 
with the problems with LASA drug names would induce the user to misperceive a 
wrong drug name as the correct drug name due to expectancy-based perceptual 
confusion.  Furthermore, the results demonstrate a pitfall from standardizing existing 
labels if careful consideration is not given to how reduced variation within and the 
number of variables that distinguish the labels can affect how people use colour of the 
labels.   
 
 Healthcare professionals are taught to be error-free and sometimes blamed for 
medication errors; yet, healthcare professionals are not immune from inherent 
limitations in human cognition.  In fact, the prevalence of LASA drug names and 
look-alike labelling/packaging and the stressful work environment make healthcare 
professionals very vulnerable to expectancy-based perceptual confusion and human 
errors in general.  To reduce the occurrence of medication errors, it is critical that 
pharmaceutical manufacturers, healthcare providers and regulators strive together to 
create a medication delivery system that does not rely on perfect performance of 
healthcare professionals.  Preventing new LASA drug names, thorough analyses of 
the labelling/packaging of existing products, end users, and the environments in which 
the product is to be used when designing/changing labelling/packaging of a product 
and finally ensuring the high legibility of the information on the label are the first and 
foremost steps.  Healthcare professionals should also acknowledge their human 
limitations and create a culture of reporting products with error-prone 






Limitations and Future Work 
 
Although this study provided understanding of how different uses of colour on a set of 
standardized labels can influence people’s behaviours in a visual search task, the 
experiment was limited in a number of ways.  Further research is necessary before the 
results of this study can be applied for labelling/packaging of injectable drug 
containers in the real world. 
 
7.1 Training 
As previously discussed, the insignificant differences in the mean response times 
across the colour conditions and across the trial types could be due to the fact that two 
to four target trials were not enough for participants to sufficiently familiarize 
themselves with the drugs and their labels for them to fully utilize the colour of the 
labels in the existing condition and in the SCC condition.  Increasing the number of 
target trials before displaying a foil trial may show significant differences in the 
response times for the target trials and the location-foil trials.  Also, becoming more 
familiar with the drugs and the labels may increase the chance of participants failing to 
differentiate the foil labels from the target labels in the existing condition. 
  
 It should be noted that the colour of the label for the highest strength level and 
colour the label for the lowest strength level of the NSL-3 drug in the practice trials 
was inadvertently switched from each other for eight participants in the SCC condition.  
The error was corrected for the remaining four participants.  The examination of the 
response times and the accuracy of the participants prior to and after correcting the 
error did not show any significant difference.  Furthermore, none of the eight 
participants reported the error, and each of the affected labels was asked only once.  
Although the error does not seem to have affected the results significantly, it is 
recommended that the results from future studies be compared to the results from this 
study with this correction in mind. 
 
7.2 Environment 
When time-constrained, interrupted and/or placed under other external stressors that 
compete for their attention, people would likely be more prone to use colour as a 
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mental shortcut to identify a drug whenever they can.  Modifying the experiment such 
that participants are given only a limited amount of time to complete their search tasks 
as well as being subject to interrupting tasks may yield different results.  Also, 
increasing the number of labels displayed per stimuli set will be closer to the 
conditions in the real world and may induce people to rely on colour more heavily to 
complete their tasks as efficiently as possible. 
  
7.3 Label Prototypes 
In the experiment, rolled-out images of the labels were displayed on a computer screen.  
Using the label prototypes attached to ampoules and/or vials would have been closer to 
the real-world scenario and may have produced different results.  In particular, since 
only a portion of the label would be visible on a curved surface unless the container is 
picked up and rotated, the coloured portions of the labels could be a stronger cue that 
differentiates one drug from another.  Conducting an experiment with paper 
prototypes on vials and ampoules was considered to be out of the scope for this study 
since doing so would have made measuring the response times and the accuracy of the 
responses challenging.    
 
7.4 Participants 
The experiment involved only 12 participants per colour condition, and there were 
large individual differences in their performances, especially for the name-foil trials.  
Furthermore, a large portion of the participants were engineering students who did not 
have any prior knowledge of injectable drugs and the danger of medication errors due 
to LASA drug names and look-alike labelling/packaging.  Healthcare professionals 
who handle injectable drugs frequently and thus aware of the issues involving LASA 
drug names and labelling/packaging may show different visual search task behaviours.  
Further studies involving a large number of healthcare professionals are recommended 
to examine how different ways of using colour on the labels can affect the actual users 
of injectable drug labels.  It should be cautioned that, when involving healthcare 
professionals as participants, careful consideration should be given to prevent the 
differences in their prior knowledge and experience with different drugs becoming a 
confounding factor.  For example, drugs that a nurse from a paediatric hospital is 
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Appendix A  
Information on the label prototypes 
 








DIN Routes of 
Administration
LOT Background colours for the 
existing condition  
(Pantone® uncoated) 
1 NSL-1 Bupropion Buspirone 1 02180669 IM, IV 120037 orange 021, red 032 
1 NSL-2 Cisplatin Carboplatin 1 00876534 IM, SC 114450 4975, 1805 
1 NSL-2 Cisplatin Carboplatin 20 00876534 IM, SC 114450 179, 3288 
1 NSL-3 Dopamine Dobutamine 1 00804312 IV, SC 121285 rhodamine red, 2745 
1 NSL-3 Dopamine Dobutamine 25 00804312 IV, SC 121285 1635 
1 NSL-3 Dopamine Dobutamine 50 00804312 IV, SC 121285 yellow, black 
2 NSL-1 Ephedrine Epinephrine 5 00392782 IM, IV 119479 warm red, reflex blue 
2 NSL-2 Glipizide Glyburide 5 00804312 IM, SC 119472 149, 4985 
2 NSL-2 Glipizide Glyburide 50 00804312 IM, SC 119472 yellow, 235 
2 NSL-3 Hydralazine Hydroxyzine 5 00897639 IV, SC 119265 382 
2 NSL-3 Hydralazine Hydroxyzine 10 00897639 IV, SC 119265 2727 
2 NSL-3 Hydralazine Hydroxyzine 15 00897639 IV, SC 119265 blue 072 
3 NSL-1 Lamivudine Lamotrigine 10 02048264 IM, IV 121344 256, 262 
3 NSL-2 Methimazole Metolazone 10 00497525 IM, SC 121285 492 
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3 NSL-2 Methimazole Metolazone 70 00497525 IM, SC 121285 2707, 032 
3 NSL-3 Nircardipine Nifedipine 10 00392693 IV, SC 129044 356 
3 NSL-3 Nircardipine Nifedipine 40 00392693 IV, SC 129044 2766 
3 NSL-3 Nircardipine Nifedipine 60 00392693 IV, SC 129044 red 032, 356 
4 NSL-1 Prednisone Prednisolone 25 02148706 IM, IV 117303 red 032, hexachrome green 
4 NSL-2 Tolazamide Tolbutamide 25 02039508 IM, SC 121058 hexacrome cyan 
4 NSL-2 Tolazamide Tolbutamide 90 02039508 IM, SC 121058 197 
4 NSL-3 Vinblastine Vincristine 25 02242652 IV, SC 121936 304, 336 
4 NSL-3 Vinblastine Vincristine 75 02242652 IV, SC 121936 101 





Recruiting participants & scheduling 
1. After receiving permission from the Engineering Society, post the recruitment 
posters in the engineering buildings. 
2. When contacted by interested prospective participants ask for their email address 
and send them the information letter.  Also suggest times for the testing in the 
email. 
 
Preparing for the testing 
1. Ensure that the application is turned on and ready to go. 
2. Turn off the phone in the testing room. 
 
Conducting the testing 
1. Greet the participant. 
2. Provide the participant with the Information Letter, and go through it with the 
participant answering any question he or she may have. 
3. Have the participant complete the Consent Form.  
4. Ask the participant to complete the Background Questionnaire. 
5. Put “Do Not Disturb” sign on the experiment room door and close the door. 
 
Vision testing 
1. Conduct the colour-blindness testing. 
2. If the participant’s colour vision is determined to be inadequate for the experiment, 
explain the results to the participant and why the participant’s colour vision is not 
adequate for the study.  Provide the feedback letter and the remuneration.  
Thank the participant. 
3. If the participant is determined to have normal colour vision, conduct the visual 
acuity test.   
4. If the participant’s near vision acuity is determined to be inadequate for the 
experiment, explain the results to the participant and why the participant’s visual 
acuity is not adequate for the study. Provide the feedback letter and the 
remuneration.  Thank the participant. 




Drug selection task 
1. Explain the task. 
The screen will show a drug name and a drug strength in mg/mL.  
Please read the information carefully.  When you are ready, pressing 
the space bar.  The screen will show 6 drug labels.  Your task will be 
to find the label for the specified drug name and drug strength, and press 
on the corresponding key on the numeric keypad. Please respond as 
accurately and as fast as possible.  Upon pressing a key, the screen will 
show another drug and drug strength for the next trial. 
 
Please keep your left hand fingers on top of the space bar to progress 
through the trials, and your right hand on top of the numeric keypad for 
entering your responses throughout the experiment session. 
 
Let’s do some practice trials first. There will be 7 practice trials. Do you 
have any question before we start the practice trials? 
 
2. Enter participant demographics to the application.   
3. Start the practice trials.  
4. After the completion of the practice trials, get ready for the experiment 
trials. 
Now, you are ready to do the actual experiment trials.  There will be 
56 trials, and it will last approximately 10 minutes.  Do you have any 
question before we start? 
 
5. Load the experiment trials. 
6. After completion of all the trials, provide the feedback letter and the 
remuneration. 













Handedness:  R  /  L 
 
Question: 
Have you worked at a pharmacy?    Y   /   N    (please circle) 
 
If yes, briefly describe what types of tasks you were responsible for.  In particular, 


















Information Letter & Consent Form 
 
Title of Project: Standardization and effective use of colour for injectable drug 
labelling 
Faculty Advisor:     Dr. Catherine M. Burns 
                                    University of Waterloo, Department of Systems Design 
Engineering 
                                    519-888-4567 Ext. 34904 or by email at c4burns@uwaterloo.ca 
Student Investigator:  Jennifer Jeon 
                                    University of Waterloo, Department of Systems Design 
Engineering 
                                    519-888-4567 Ext. 34904 or by email at hwjeon@uwaterloo.ca 
Purpose: Harm from medication errors is the most common type of adverse medical 
events.  Poor labelling has been identified as a major contributing factor of medication 
errors.  The effectiveness of standardizing label design and use of colour in reducing 
medication errors remains unresolved.  The study aims to investigate potential effects 
of standardizing label designs and eliminating colour, applying existing colour schemes 
and applying a drug strength colour coding system to injectable labels on the visual 
search task involved in selecting a drug from a storage area.  The objective will be 
achieved by comparing the visual search task performance on the standardized label 
prototypes with the three types of colour condition.  The accuracy and speed of 
responses will be used as measures of the task performance. 
Format:  The testing will consist of a vision testing and a visual search task and will 
be held at the Advanced Interface Design Lab located in E2 1303N.  Your participation 
is expected to last 30 minutes including set-up.  First, your vision will be tested in 
terms of near-vision acuity, colour-blindness and contrast sensitivity.  The testing will 
be done using the Waterloo Near Vision Test (NVT) card and the Ishihara 
Pseudoisochromatic Plates.  Waterloo Near Vision Test (NVT) card consists of lines of 
letters of different sizes and character-to-background contrast ratios designed to test 
your near vision acuity and contrast sensitivity. You will be asked to hold the NVT card 
at 40 cm away from your eyes and read aloud the lines of letters until you reach the 
smallest line that you can read.  Ishihara Pseudoisochromatic Plates consist of a 
number of coloured plates, each of which contains a circle made of many dots of 
different colours and sizes that are designed to test for colour blindness.  You will be 
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asked to speak aloud what you see in each of the 17 plates (Plate 1 to 17) of the 
Ishihara Pseudoisochromatic Plates.  It will take approximately 15 minutes to 
complete the vision testing.  If your colour vision is determined to be appropriate for 
the study, you will be asked to perform two sets of label reading tasks.   
The visual search task will consist of 56 trials. There will be 7 practice trials for you to 
familiarize yourself with the task.  For each trial, you will be shown a drug name and 
its strength on a monitor.  Then, the monitor will show a screen with 6 drug labels.  
Your goal will be to find the drug label that corresponds to the drug name and strength 
previously displayed, and input your response by pressing a key on the keyboard as 
accurately and quickly as possible.  You will be given as much time as needed to 
complete the tasks.  The test monitor may take general notes on your performance. 
Although there are no expected risks/side effects associated with participation in this 
research, should you feel that you can no longer carry out the tasks for any reason, 
you can request to take a break or stop the experiment anytime by informing the test 
monitor. 
There will be a monetary remuneration for your participation at the rate of $5 per half 
an hour with a limit of $10.  If you withdraw from the study at any point or your vision 
is determined to be inappropriate for the study, your remuneration will be $5. 
You may not benefit personally from your participation in this study.  However, the 
information obtained from this research may lead to improved labels for 
pharmaceuticals and reduce errors in medicine. In addition, the findings from the study 
may help both healthcare and human factors professionals gain understanding of how 
human factors professionals can contribute to improving the quality and safety of 
patient care. 
All information collected from participants in this study will be aggregated.  Thus, your 
name will not appear in any report, publication or presentation resulting from this 
study.  The data, with identifying information removed, will be securely stored for 3 
years in a locked office in the research laboratory. Electronic data will be kept on a 
computer in the lab and on completion of analyses it will be burnt onto a DVD, stored 
in the lab for 3 years, and then destroyed. 
If you have any questions about participation in this study, please feel free to ask the 
researchers.  If you have additional questions at a later date, please contact Dr. 
Catherine Burns at ext. 34904.  You are under no obligation to participate and may 
withdraw from the study at any time by advising the researcher of this decision. 
I would like to assure you that this study has been reviewed and received ethics 
clearance through the Office of Research Ethics at the University of Waterloo. However, 
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the final decision about participation is yours. If you have any comments or concerns 
resulting from your participation in this study, you may contact the Director, Office of 
Research Ethics at 519-888-4567 ext. 36005.
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Consent of participant 
I agree to participate in a study being conducted under the supervision of Dr. Catherine 
M. Burns at the University of Waterloo.  I have made this decision based on the 
information I have read in the Information-Consent Letter and have had the 
opportunity to receive any additional details I wanted about the study.  I understand 
that I may withdraw this consent at any time by telling the researcher.   
I also understand that this project has been reviewed by, and received ethics clearance 
through, the Office of Research Ethics at the University of Waterloo (519-888-4567 ext. 
36005), and that I may contact this office if I have any concerns or comments resulting 
from my involvement in this study. 
Name:  ___________________________       
Signature:  _______________________________      Date:    __________________
____ 
Witness Signature: _______________________ 
 
 
 
